WO2007088181A1 - Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations - Google Patents

Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations Download PDF

Info

Publication number
WO2007088181A1
WO2007088181A1 PCT/EP2007/050964 EP2007050964W WO2007088181A1 WO 2007088181 A1 WO2007088181 A1 WO 2007088181A1 EP 2007050964 W EP2007050964 W EP 2007050964W WO 2007088181 A1 WO2007088181 A1 WO 2007088181A1
Authority
WO
WIPO (PCT)
Prior art keywords
butyl
phenyl
methyl
dichloro
amino
Prior art date
Application number
PCT/EP2007/050964
Other languages
French (fr)
Inventor
Daniel Jasserand
Matthias Mentzel
Janis Jaunzems
Werner Benson
Ulf Preuschoff
Michael Firnges
Holger Sann
Reinhard Brückner
Martinus Adolfs
Amos Attali
Uwe Schön
Peter Smid
Dania Reiche
Andrew Christopher Mccreary
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Priority to EP07704286A priority Critical patent/EP1979319A1/en
Priority to AU2007211475A priority patent/AU2007211475A1/en
Priority to JP2008552803A priority patent/JP2009525308A/en
Priority to CA002641817A priority patent/CA2641817A1/en
Publication of WO2007088181A1 publication Critical patent/WO2007088181A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Novel dual NK2/NK3-antagonists novel dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation.
  • the present invention relates to novel dual NK2/NK3-antagonists and also to pharmaceutical compositions comprising these compounds. Furthermore, the invention relates to processes for the preparation of the novel dual NK2/NK3- antagonists.
  • Neurokinins also kown as tachykinins, include the naturally-occurring neuropeptides substance P, neurokinin A and neurokinin B.
  • the tachykinins act as agonists of receptors occurring in larger mammals and humans, such as the neurokinin-1 receptor, the NK-2 receptor and the NK-3 receptor.
  • Artificially prepared compounds which are antagonistic to tachykinin receptors are usually classified according to their relative ability to bind to one or more of the aforementioned three receptor subtypes. In the physiological process the tachykinins play e.g. an important part in the transmission of pain, emesis, neurogenic inflammation, bladder inflammation, inflammatory joint diseases or asthmatic complaints.
  • Gerspacher Progress in Medical Chemistry, 2005, Vol. 43, 49 to 103 giving an overview about recent developments on selective (NK1- or NK2- or NK3-receptor antagonists) and on combined (NK1/NK2-; NK1/NK2/NK3-; and NK2/NK3-) receptor antagonists.
  • NK2/NK3-receptor antagonists appear to be limited by two approaches from GSK and Sanofi.
  • GSK preferred a stepwise modification of the structure of the NK3 selective antagonist talnetant, by the introduction of a variety of substituents at the meta-position of the quinoline moiety of the molecule.
  • a highly effective compound is the following:
  • a group of novel linear core-compounds is distinguished by properties antagonistic to tachykinin receptors, in particular to NK2 and/or NK3-receptors. Accordingly, the group of compounds according to the invention appears particularly suitable for the treatment of peripheral disorders in which tachykinins, in particular neurokinin A and/or neurokinin B, participate as transfer agents, for example for the treatment and/or prophylaxis of any pathology where either neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or both neurokinin A and neurokinin B and/or NK2 and NK3-receptors are involved.
  • the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular systems and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases.
  • the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large- cell lung cancers, diseases of the immune system, bipolar disorders; migraine; pain, anxiety, depression, cognitive disorders, stress- related so
  • R1 is selected from the group consisting of: alkyl and cycloalkyl
  • R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring;
  • R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
  • X is selected from the group consisting of: CR6 and nitrogen;
  • R5 is selected from the group consisting of: alkyl optionally substituted with (CO) m NR9R10, cycloalkyl optionally substituted with (CO) m NR9R10, and NR7R8;
  • R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and
  • R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6-membered ring, none of the ring atoms is replaced by carbonyl; R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and physiologically compatible acid addition salts of compounds of Formula I.
  • compositions comprising the compounds of Formula I.
  • Still another subject of the present invention are processes for the preparation of the compounds of Formula I.
  • substituents are or contain alkyl and/or alkylene, these may each be straight-chain or branched and possess from 1 to 20 carbon atoms, preferably from 1 to 10 carbon atoms, more preferably from 1 to 7 carbon atoms and even more preferably from 1 to 4 carbon atoms.
  • the most preferred straight-chain alkyl and/or alkylene group is methyl and/or methylene, respectively.
  • the most preferred branched alkyl and/or alkylene group is isopropyl and/or isopropylene, respectively.
  • substituents are or contain cycloalkyl and/or cycloalkylene, these may possess from 1 to 20 carbon atoms, preferably from 1 to 10 carbon atoms, more preferably from 1 to 7 carbon atoms and even more preferably from 1 to 4 carbon atoms.
  • the most preferred cycloalkyl and/or cycloalkylene groups are cyclopentyl and cyclohexyl and/or cyclopentylene and cyclohexylene, respectively.
  • substituents are or contain alkenyl and/or alkenylene, these may each be straight-chain or branched and possess from 2 to 20 carbon atoms, preferably from 2 to 10 carbon atoms, more preferably from 2 to 7 carbon atoms and even more preferably from 2 to 4 carbon atoms.
  • the most preferred alkenyl and/or alkenylene group is ethenyl and/or ethenylene, respectively.
  • substituents in compounds of Formula I are or contain halogen, fluorine, chlorine or bromine are suitable. Chlorine is preferred. Where substituents in compounds of Formula I are or contain carboxyalkyl, -OC(O)alkyl or C(O)Oalkyl are suitable, OC(O)alkyl is preferred.
  • substituents in compounds of Formula I are or contain aryl and/or arylene, monocyclic, bicyclic, tricyclic and tetracyclic aromatic ring systems are suitable. Phenyl is preferred. Where substituents in compounds of Formula I are or contain heteroaryl and/or heteroarylene, monocyclic, bicyclic, tricyclic and tetracyclic aromatic ring systems containing at least one heteroatom such as nitrogen are suitable.
  • substituents in compounds of Formula I are or contain heterocyclic rings
  • monocyclic, bicyclic, tricyclic and tetracyclic non-aromatic ring systems containing at least one, if not two or three or even four heteroatoms such as nitrogen and/or sulfur and/or oxygen are suitable.
  • a monocyclic ring system is preferred.
  • Nitrogen and/or oxygen are preferred as heteratoms.
  • R7 and R8 and/or R9 and R10 form together a 5- to 7-membered ring and wherein in a particular embodiment, each of these rings independently optionally contain an additional heteroatom, such heteroatom may be selected from nitrogen, oxygen and sulphur, preferably oxygen.
  • R1 is methyl
  • R3 and R4 are independently selected from the group consisting of: hydrogen, fluoro, chloro, preferably hydrogen or chloro.
  • R7 and R8 form together a 6-membered ring or R7 and R8 form together a 6-membered ring substituted by CONR9R10.
  • R9 and R10 are both methyl, or R9 and R10 form together a 6-membered ring, or R9 and R10 form together a 5-membered ring substituted by carbonyl.
  • R2 is selected from the group consisting of: C 1 to C 20 alkyl; C 3 to C 20 cycloalkyl; C 2 to C 20 alkenyl;
  • each of R1 1 to R16 are independently selected from the group consisting of: hydrogen, fluoro, chloro, bromo, hydroxyl, alkoxy, cyano,
  • N(H)C(O)Oalkyl aminoalkyl, dialkylamino, OCF 3 , CF 3 , carboxyalkyl, S(O) 2 NH 2 , phenyl, alkyl, and cycloalkyl; wherein each of R18 and R19 are independently selected from the group consisting of: hydrogen, cyano and aryl; wherein t is 0 or 1 ; wherein each Q is independently selected from the group consisting of: CR1 1 and N; wherein Y is selected from the group consisting of: CH, N and NO; wherein Z is selected from the group consisting of: C-benzyl, NH, N-benzyl, N-alkyl, O and S; wherein each V is independently selected from the group consisting of: N and CR17; and; wherein R17 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, and thioalkyl.
  • R5 is selected from the group consisting of:
  • the compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula Il wherein R1 to R4 have the above meanings, with a compound of formula
  • R5 has the above meaning, to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt.
  • the compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula III
  • R2 has the above meaning, to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt.
  • the compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula X
  • Q is selected from the group consisting of: halogen, preferably, bromo or iodo; and methylsulfonyl; with a compound of formula III
  • the compounds of Formula Il can be prepared by reacting a compound of formula VII
  • the compounds of Formula IV can be prepared in a similar manner as suggested for compounds of Formula II, by selecting an appropriate R2.
  • the compounds of Formula VII are known per se or can be prepared by the person skilled in the art from known compounds in known manner.
  • the compounds of Formula X can be prepared by reacting a compound of the general Formula IX with HHalogen, preferably HBr or HI to deliver compounds of Formula X wherein Q is a halogen, preferably bromo or iodo, or, alternatively, with methanesulfonylchloride to deliver compounds of Formula X wherein Q is methylsulfonyl
  • the compounds of Formula I may be isolated from the reaction mixture and purified in known manner. Acid addition salts may be converted into the free bases in conventional manner, and these may if desired be converted in known manner into physiologically compatible acid addition salts.
  • Physiologically compatible salts of compounds of Formula I are their conventional salts with inorganic acids, for example sulphuric acid, phosphoric acids or hydrohalic acids, preferably hydrochloric acid, or with organic acids, for example lower aliphatic monocarboxylic, dicarboxylic or tricarboxylic acids such as maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, or with sulphonic acids, for example lower alkanesulphonic acids such as methanesulphonic acid or trifluoromethanesulphonic acid, or benzenesulphonic acids optionally substituted in the benzene ring by halogen or lower alkyl, such as p- toluenesulphonic acid.
  • the compounds of Formula I contain in the ⁇ -position to the ring nitrogen atom in the 4-position of the piperidine or piperazine ring, respectively, an asymmetrical carbon atom, namely the carbon atom *C bearing the phenyl ring substituted by R3 and R4.
  • the compounds of Formula I may be present in several stereo isomeric forms.
  • the present invention covers both the mixtures of optical isomers and the isomerically pure compounds of Formula I.
  • stereochemical ⁇ uniform compounds of Formula I can also be obtained.
  • the stereochemical ⁇ uniform compounds of Formula I can be obtained from the mixtures of optical isomers in known manner, for example by chromatographic separation on chiral separating materials or by reaction with suitable optically active acids, for example tartaric acid or 10-camphorsulphonic acid, and subsequent separation into their optically active antipodes by fractional crystallisation of the diastereomeric salts obtained.
  • the compounds of Formula I and their acid addition salts have properties which are antagonistic to tachykinin receptors and are therefore suitable for the treatment of pathological conditions in larger mammals, particularly humans, in which tachykinins are involved as transfer agents.
  • the group of compounds according to the invention is distinguished by a particularly beneficial action profile which is characterised by a high selectivity to NK2 and/or NK3-receptors. Furthermore, the group of compounds according to the invention is distinguished by good compatibility even over prolonged periods of administration, and by comparatively good oral availability.
  • the compounds of Formula I are suitable in particular for inhibiting processes in which tachykinins, such as neurokinin A, which bind to NK2-receptors, and/or neurokinin B, which which to NK3-receptors are involved.
  • tachykinins such as neurokinin A
  • neurokinin B which bind to NK2-receptors
  • neurokinin B which which to NK3-receptors are involved.
  • the compounds of Formula I are suitable in particular for the treatment and/or prophylaxis of any pathology where either neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or both neurokinin A and neurokinin B and/or NK2 and NK3-receptors are involved.
  • R2 is a cyano-substituted naphthalene ring system
  • R2 is a cyano-substituted naphthalene ring system
  • compounds of Formula I wherein R2 is a cyano-substituted naphthalene ring system are suitable in particular for the treatment and/or prophylaxis of any pathology where substance P and/or NK1 -receptors, or neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or any combination of two or all three substance P, neurokinin A and neurokinin B and/or NK1 , NK2 and NK3-receptors are involved.
  • the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular system and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases.
  • the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large- cell lung cancers, diseases of the immune system, bipolar disorders; migraine; pain, anxiety, depression, cognitive disorders, stress- related so
  • IBS irritable bowel syndrome
  • Typical symptoms for the diagnosis of IBS are described, for example, in W. G. Thompson et al., Gastroenterology International 2 (1989) 92-95 or in W.G. Thompson et al., GUT 45/II (1999) II43-II47, and are generally known among experts by the term "Rome Criteria”.
  • the essential symptoms of IBS accordingly include pains in the lower abdomen, which appear to be due to hypersensitivity of the visceral afferent nervous system, and anomalies in bowel movement, such as constipation, diarrhoea or alternating constipation and diarrhoea.
  • IBD inflammatory bowel disease
  • the compounds according to the invention furthermore appear suitable for the treatment of other disorders in which tachykinins and in particular neurokinin A are involved as transfer agents.
  • These disorders include for example neurogenic inflammation, inflammatory joint diseases such as rheumatic arthritis, asthmatic complaints, allergic disorders, disorders of immune regulation, bladder inflammation or also functional dyspepsia.
  • Another advantage of the compounds of the present invention is the synergistic effect between the NK2- and NK3-profile.
  • Another advantage of the compounds of the present invention is their very balanced combined NK2- and NK3-profile.
  • the affinity of test compounds for NK1 -receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site. The tests were performed at Solvay Pharmaceuticals, Weesp, The Netherlands.
  • the radiolabel used in this assay is [ 3 H]-Substance P.
  • Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK1 -receptor was stably expressed. Membranes were incubated with [ 3 H]- Substance P in the absence or presence of test compounds at different concentrations, diluted in a buffer system. Separation of bound radioactivity from free radioactivity was done by filtration through glass fiber filters (Packard GF/B) with several washings with ice-cold buffer solution. Bound radioactivity was measured with a liquid scintillation counter (total binding). Unspecific binding was determined by incubation with an excess (1 ⁇ mol/l) of unlabeled Substance P.
  • Specific binding is obtained by subtraction of the unspecific from the total binding.
  • Radioactivity of the specific binding was plotted against the concentration of the test compound and IC 50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated.
  • the inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi).
  • the pKi value describes the potency of a test compound to bind to a receptor.
  • Table 1 Binding potency of the test substances to NK1 -receptors in vitro
  • the affinity to human NK1-receptors was determined in each case by at least three measurements of the test substances in concentration series of 1 (H> to 10 ' " O mol/l. The average result of all measurements is listed above.
  • the compounds of Example No. 1 , 4, 8 to 1 1 , 14, 15, 24, 49, 55, 56, 65, 70, 80, 82, 83, 89, 92, 93, 98, 101 to 103, 105, 108, 1 16, and 125 to 127 exhibited pKi values of at least 7.0 in this test model.
  • the compounds of Example No. 1 1 , 93, 98, 101 , 102 and 126 exhibited pKi values of at least 8.0. 2. Determination of the binding potency of the test substances to NK2-receptors in vitro
  • the affinity of test compounds for NK2-receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site.
  • the radiolabel used in this assay is [ 3 H]-SR 48968 (saredutant).
  • Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK2-receptor was stably expressed. Membranes were incubated with [ 3 H]-saredutant in the absence or presence of test compounds at different concentrations, diluted in a buffer system. Separation of bound radioactivity from free radioactivity was done by filtration through glass fiber filters (Packard GF/B) with several washings with ice-cold buffer solution. Bound radioactivity was measured with a liquid scintillation counter (total binding). Unspecific binding was determined by incubation with an excess (0.1 ⁇ mol/l) of unlabeled saredutant.
  • Specific binding is obtained by subtraction of the unspecific from the total binding.
  • Radioactivity of the specific binding was plotted against the concentration of the test compound and IC 50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated.
  • the inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi).
  • the pKi value describes the potency of a test compound to bind to a receptor.
  • Example No. 1 to 47, 49 to 53, 55, 56, 58, 59, 61 , 63 to 104 and 124 to 127 the affinity to human NK2-receptors was determined in each case by at least three measurements of the test substances in concentration series of 10 ⁇ 6 to 10 '" O mol/l. The average result of all measurements is listed above. All the aforementioned test substances exhibited pKi values of at least 7.0 in this test model.
  • the affinity of test compounds for NK3-receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site.
  • the radiolabel used in this assay is [ 3 H]-SR 142801 (osanetant).
  • Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK3-receptor was stably expressed. Membranes were incubated with [ 3 H]-osanetant in the absence or presence of test compounds at different concentrations, diluted in a buffer system.
  • Specific binding is obtained by subtraction of the unspecific from the total binding.
  • Radioactivity of the specific binding was plotted against the concentration of the test compound and IC 50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated.
  • the inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi)
  • the pKi value describes the potency of a test compound to bind to a receptor.
  • Example No. 1 For the compounds of Example No. 1 , 3 to 7, 9 to 16, 18, 19, 21 to 23, 25, 26, 29 to 33, 36 to 41 , 43 to 47, 49 to 57, 60, 63 to 87, 89 to 91 , 95, 97 to 104, and 124 to 126 the affinity to human NK3-receptors was determined in each case by at least three measurements of the test substances in concentration series of 10 ' ⁇ to 10 ' " O mol/l. The average result of all measurements is listed above. All the aforementioned test substances exhibited pKi values of at least 7.0 in this test model. The compounds of Example No. 1 , 3 to 10, 14, 15, 18, 23, 36, 43, 49 to 51 , 53 to 56, 67, 68 and 83 exhibited pKi values of at least 8.0.
  • CHO fibroblast cells, stably expressing cloned human NK1 , NK2 or NK3-receptors.
  • the NK receptor is coupled to G q .
  • the activation of the G q protein by ligand binding to the receptor leads to a mobilization of intracellular calcium and phosphorylation of
  • the growth-medium was aspirated out of the well without disturbing the confluent cell layer and 100 ⁇ l loading medium (HBSS, 4 ⁇ M FLUO-4, 0.005% (w/v) pluronic acid, 2.5mM probenecid, 20 mM HEPES, pH 7.4) was dispensed into each well using an automatic pipettor system (Multidrop, Labsystems). Pluronic acid was added to increase dye solubility and dye uptake into the cells, whereas probenecid, an anion exchange inhibitor, was added to the loading medium to increase dye retention in the cells. The cells were incubated in a 5% CO 2 incubator at 37 0 C for 40 minutes.
  • the cells were washed three times with wash- buffer (HBSS, 2.5 mM probenecid, 20 mM HEPES, pH 7.4) to reduce basal fluorescence.
  • wash- buffer HBSS, 2.5 mM probenecid, 20 mM HEPES, pH 7.4
  • the buffer was aspirated and replaced with 100 ⁇ l washing buffer.
  • 50 ⁇ l of the compound (final concentration ranges from 10 ⁇ M to 1.4 nM) were applied 7 min prior to addition of substance P (final concentration: 10 '8 M; NK1 agonist) or NKA (final concentration: 10 '7 M; NK2 agonist).
  • the FLIPR setup parameters were set to 0.4 sec exposure length, filter 1 , 50 ⁇ l fluid addition, pipettor height at 125 ⁇ l, dispense speed 40 ⁇ l/sec without mixing. Maximal fluorescence changes were obtained using the statistic function of the FLIPR software, and data plotted using GraphPad Prism 4. All points were expressed as a percentage inhibition of the control agonist. IC 50 values were determined using sigmoidal dose-response curve fitting. Antagonist potencies (pA 2 ) values were calculated using equation:
  • PA 2 -log (IC 50 /(1 + [L] / EC 50 )),
  • [L] is the concentration of the agonist (substance P for NK-
  • NK2 test, NKb for NK3 test), and the EC 50 is the potency of the agonist at the respective human cloned NK receptor (EC 50 substance P: 10 "96 M; EC 50 NKA: 10 "8 8 M, EC 50 NKB: 10 "88 M).
  • EC 50 substance P 10 "96 M
  • EC 50 NKA 10 "8 8 M
  • EC 50 NKB 10 "88 M
  • NK3 antagonism Ca 2+ measurements using aequorin for NK3 activity NK3 antagonism was measured in a cell line expressing the human NK3 receptor and mitochondrially targeted apoaequorin.
  • cells expressing apoaequorin are incubated with coelenterazine, which is the chromophore co-factor of aequorin.
  • coelenterazine which is the chromophore co-factor of aequorin.
  • senktide Upon incubation of the cells with senktide, a potent agonist on NK3, intracellular calcium concentration increases.
  • DMEM/F-12 nutrient mixture according to Ham
  • FCS 10% FCS
  • coelenterazine was added to a final concentration of 5 ⁇ M and cells were stirred at room temperature for 4 hours.
  • Loaded cells were diluted in DMEM/F12 without phenolred and supplements to a density of 2.8x105 cells/ml, pre-heated to 37°C, and stirred for 60min at room temperature.
  • pA2 plC50 + log [(L / EC50)-1],
  • plC50 is the negative logarithm of the IC50 value of the test compound that was obtained from concentration-effect relationships
  • L is the concentration of senktide and EC50 its potency at the human cloned NK3 receptor (EC50 senktide: 10- 8.8M).
  • Table 6 pA 2 data for NK3
  • NK1 -antagonistic action of test compounds was tested in aortic ring preparations isolated from guinea pigs.
  • the preparations were kept in an oxygenated nutrient solution kept at 37°C.
  • the preparations were fixed to a hook and connected to force displacement transducers. Contractions/relaxations were recorded on a pen recorder.
  • the preparations were given a medium tonus by addition of phenylephrine.
  • Table 7 Functional NK1 -antagonism of the test substances on isolated guinea pig tissue
  • the NK2 antagonistic action of test compounds was tested in gall bladder preparations isolated from guinea pigs. The preparations were kept in an oxygenated nutrient solution kept at 37°C. For measuring contraction of the gall bladder muscle, the preparations were fixed to a hook and connected to force displacement transducers. Contractions were recorded on a pen recorder. The NK2-receptors were stimulated with the NK2-receptor agonist neurokinin A, causing a contraction of the muscle. Before (predrug) and after the administration of the test compound such contractions were measured and quantified in percent of the predrug contraction. 2-3 concentrations of the test compound were applied showing the inhibition of the receptor stimulation concentration dependently.
  • the plC 5 o value indicates the inhibitory potency of the test compounds to the NK2-receptor.
  • Table 8 NK-2-receptor-antagonistic effectiveness of the test substances of Formula I on the guinea pig gall bladder in vitro
  • NK3-receptor antagonism of test compounds in tissue isolated from guinea pigs.
  • the NK3-antagonistic action of test compounds was tested in ileal preparations isolated from guinea pigs.
  • the preparations were kept in an oxygenated nutrient solution kept at 37°C.
  • the preparations were fixed to a hook and connected to force displacement transducers. Contractions were recorded on a pen recorder.
  • NK3 agonists reduce the body temperature of gerbils.
  • the senktide-induced hypothermia can be antagonized by administering compounds with NK3-antagonistic properties. Measuring the level of hypothermia is indicative for the degree of activity of the test compounds. The own effect of the tested compound is assessed in the same experiment to exclude an additional hyperthermic effect.
  • Male gerbils with a body weight between 60 to 90 g are housed in groups under normal day-night rhythm and under constant environmental temperature (room temperature: 21 ⁇ 2 0 C) with a constant relative humidity level (50 ⁇ 10%). Water and food are freely available.
  • Reference agonist Senktide 0.03 mg/kg sc.
  • Antagonists see example compounds in table X.
  • the animals are weighted and marked 60 minutes prior to the agonist administration.
  • the agonist Senktide is administered (sc).
  • t 15 minutes the temperature is measured orally, and registered with a 0.1 0 C accuracy after a 10 second reading. This way, animals are measured every 60 sec.
  • the vehicle/vehicle group is used as reference for the analysis of the own effect; whereas the vehicle/senktide group is used for comparison for the interaction test (i.e. example compounds/senktide groups).
  • Table 1 1 Inhibition of temperature increase at a dose of 10 mg/kg after parenteral (ip) administration
  • NK3 agonists increase the blood pressure in guinea pigs.
  • the senktide- induced hypertension can be antagonized by administering compounds with NK3- antagonistic properties. Measuring the level of hypertension is indicative for the degree of activity of the test compounds. The own effect of the tested compound is assessed in the same experiment to exclude an additional hypertensional effect.
  • Blood pressure was measured with a strain gauge transducer connected to a computer via an amplifier.
  • NK3-receptor agonist senktide 0.4 ⁇ g/kg i.v.; 0.5 ml/kg
  • the mean value of the increase in blood pressure served as the pre-drug hypertensive effect of senktide.
  • the test compound was given as an infusion over 10 min (0.1 ml/min), immediately followed by an injection of 0.4 ⁇ g/kg senktide and the peak increase in mean arterial blood pressure determined.
  • Up to 5 cycles of additive test compound dosages were applied and the hypertensive effect of senktide determined after each dose.
  • test compound The effect of the test compound on the peak rise in blood pressure induced by senktide is expressed as percentage relative to the pre-drug value.
  • ID 50 values dose that produces a 50% inhibition of the senktide response
  • the effect of the vehicle on the senktide induced pressure response was determined on regular base.
  • NK3- receptor agonist senktide 0.4 ⁇ g/kg i.v.; 0.5 ml/kg
  • the first senktide injection was approximately 80 to 90 minutes post dosing.
  • the mean value of the increase in blood pressure served as the hypertensive effect of senktide in that animal.
  • the mean hypertensive effect of senktide following vehicle treatment served as the control value (100%).
  • the effect of each test compound dose on the peak rise in blood pressure induced by senktide is expressed as percentage relative to this control value and averaged per dose group.
  • ID 50 values dose that produces a 50% inhibition of the senktide response
  • Senktide (0.8 ⁇ g/ml) was dissolved in saline.
  • the test compounds were dissolved in 40% hydroxypropyl- ⁇ -cyclodextrine (HPCD) containing 10% DMSO, diluted with saline and administered intravenously in cumulative dose ranges.
  • HPCD hydroxypropyl- ⁇ -cyclodextrine
  • a vehicle group of animals received the corresponding HPCD/DMSO solutions instead of the test compound.
  • the test compound was suspended in 1 % methylcellulose.
  • a vehicle group of animals received the corresponding HPCD/DMSO solutions instead of the test compound.
  • Table 12 Inhibition of blood pressure as ID 50 -value after intravenous (iv) and oral (po) administration
  • i.v. intravenous
  • NK2-antagonistic effects in three different organ systems (respiratory tracts, colon and circulation) and NK1 -antagonistic effects (rapid drop in blood pressure) in an animal simultaneously.
  • Pirbright-White guinea pigs of a body weight of 500-700 g were anaesthetised with ketamine/xylazine (67/13 mg/kg subcutaneously, initial dose, further doses administered as required).
  • the animals were provided with an intravenous catheter in order to administer the substance and an intra-arterial catheter to measure the blood pressure.
  • the animals were artificially ventilated via a tracheal cannula and the respiratory pressure was recorded by means of a pressure transducer.
  • a balloon was introduced into the distal colon of the animals for manometric recording of colon motility by means of a pressure transducer.
  • NKA injection resulted in an increase in respiratory pressure (bronchoconstriction) and colonic pressure, and in a biphasic drop in blood pressure.
  • the doses of the test substances are given as ED50 values which each result in a response to the NKA test stimulus which is reduced to 50% of the initial value, as characteristic variables for the individual measurement parameters bronchoconstriction, colonic pressure and change in blood pressure mediated by NK1 or NK2.
  • the antagonistic effects of the test substances were first investigated in cumulative form, the time of the NKA test stimulus being 1 min after the administration of the respective doses of the test substances had ended. These ED50 values obtained from cumulative dose effect curves are plotted in table 13.
  • Table 13 NK1- and NK2-receptor-antagonistic potency of the test substances of Formula I on guinea pigs in vivo after intravenous administration
  • the measured values plotted in table 14 above show, inter alia, that the compounds of Example No. 1 1 after cumulative administration i.v. (detection of the antagonism 1 min. after the administration of test substance had ended) caused a marked NK-1 -receptor-antagonistic activity on the early hypotension.
  • the data show further that compounds of all Example No. caused a marked NK2-receptor-antagonistic activity of colon motility, late drop in blood pressure and respiratory resistance.
  • the action of the NKA test stimulus was determined at different times (1 , 30, 60, 90, 120, 150 and 180 min.) after oral administration of the test substances.
  • the antagonistic effects of the test substances were then determined as "area under the curve" ("AUC") over the investigation period after administration of the test substances (1 - 180 min after administration) and the ED50 values after oral administration obtained therefrom were plotted in table 14.
  • Table 14 NK1- and NK-2-receptor-antagonistic potency of the test substances of Formula I on guinea pigs in vivo after oral administration
  • Example 1 1 was also active as NK1 receptor antagonists.
  • the compounds of Formula I may be administered in conventional pharmaceutical preparations.
  • the doses to be used may vary individually and will naturally vary according to the type of condition to be treated and the substance used. In general, however, medicinal forms with an active substance content of 0.2 to 200 mg, in particular 1 to 50 mg, active substance per individual dose are suitable for administration to humans and larger mammals.
  • the compounds may be contained according to the invention, together with conventional pharmaceutical auxiliaries and/or carriers, in solid or liquid pharmaceutical preparations. Examples of solid preparations are preparations which can be administered orally, such as tablets, coated tablets, capsules, powders or granules, or alternatively suppositories.
  • preparations may contain conventional pharmaceutical inorganic and/or organic carriers, such as talcum, lactose or starch, in addition to conventional pharmaceutical auxiliaries, for example lubricants or tablet disintegrating agents.
  • Liquid preparations such as suspensions or emulsions of the active substances may contain the usual diluents such as water, oils and/or suspension agents such as polyethylene glycols and the like.
  • auxiliaries may additionally be added, such as preservatives, taste correctives and the like.
  • the active substances may be mixed and formulated with the pharmaceutical auxiliaries and/or carriers in known manner.
  • the active substances may for example be mixed with the auxiliaries and/or carriers in conventional manner and may be wet or dry granulated.
  • the granules or powder can be poured directly into capsules or be pressed into tablet cores in conventional manner. These may be coated in known manner if desired.
  • LC-MS data were obtained by the following conditions: Instrument- Description: API 100 Single Quad, PE Applied Biosystems
  • the LC-MS data were obtained by the following conditions: Instrument- Description: ZQ Single Quad, Waters / Micromass Alliance HT 2795, Waters PL-ELS 1000 Lightscattering-Detector, Polymer Labs
  • Example 1 Synthesis of ⁇ /-[(2S)-2-(3,4-dichloroprienyl)-4-oxobutyl1- ⁇ /-methyl- benzamide as starting material for the preparation of example compounds 1 , 2 and 99
  • Example 2 Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1- ⁇ /, ⁇ /-dimethyl-1 ,4'-bipiperidine-4'-carboxamide (example compound 1 )
  • the mixture was concentrated to dryness in vacuum and re-dissolved in 300 ml ethyl acetate, 50 ml of MTBE and 6 g of KOH dissolved in 100 ml of water.
  • the organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 100 ml of water.
  • the organic solution was dried on sodium sulphate and concentrated to dryness to give 27 g of the raw base as a foam. 17 g of raw base were dissolved in 30 ml of methylene chloride at room temperature to which 13 ml of 5N HCI in isopropanol were added and a solution was obtained. To the solution were added 500 ml of MTBE and a solid appeared.
  • Raw base purified by dissolution in water in the presence of concentrated HCI gives after elimination of insoluble by- products by extraction with MTBE and basification by means of KOH of the water phase and subsequent extraction of the base using methylene chloride a pure base as a yellowish compound with a 90%-yield.
  • Optical rotation; -17.8° (c 1 % in methanol).
  • Example 3 Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1- ⁇ /-methyl-1 ,4'-bipiperidine-4'-carboxamide (example compound 2)
  • the mixture was concentrated to dryness in vacuum and re-dissolved in 300 ml ethyl acetate, 50 ml of MTBE and 6 g of KOH dissolved in 100 ml of water.
  • the organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 100 ml of water.
  • the organic solution was dried on sodium sulphate and concentrated to dryness to give 27 g of the raw base as an foam. 17 g of raw base were dissolved in 30 ml of methylene chloride at room temperature to which 13 ml of 5N HCI in isopropanol were added and a solution was obtained. To the solution were added 500 ml of MTBE and a solid appeared.
  • Example 4 Synthesis of 1-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1- ⁇ /, ⁇ /-dimethyl-4-pyrrolidin-1-ylpiperidine-4-carboxamide (example compound 99):
  • the reaction was quenched with 1 L of water.
  • the mixture was extracted with ethyl acetate (3x 1 L).
  • the organic layer was washed with 500 ml of a saturated solution of sodium chloride in water.
  • the combined water layers were extracted with dichloromethane (2x 1 L).
  • the combined organic layers were evaporated to dryness.
  • the crude mixture was further purified over Silica (eluent: CH 2 CI 2 /Me0H, 100/0 to 95/5, v/v) yielding 68.4 g of the target compound (207 mmol, 67%) as light yellow solid.
  • Benzyl-N,N-dimethyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxamide (29 g, 88 mmol) was dissolved in fert.-Butanol / water (600 ml, 9/1 , v/v).
  • Pd-C (6 g, 10%, wet) was added and the mixture was stirred in hydrogen atmosphere (5 bar) at 5O 0 C for 16 h.
  • NMR analysis revealed complete conversion.
  • the Pd-C was removed by filtration over celite. The celite crop was washed with fert.-Butanol / water (100 ml_, 9/1 , v/v). The volatiles were removed by evaporation in vacuum.
  • Example 7 Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichloro-phenyl)- butyl1- ⁇ /, ⁇ /-dimethyl-1 ,4'-bipiperidine-2-carboxamide (example compound 100)
  • Example 8 Synthesis of ⁇ /-[(2S)-2-(3,4-dichlorophenyl)-4-(4- ⁇ 1-[(dimethylamino)- carbonyl1cvclohexyl)piperazin-1-yl)butyl1- ⁇ /-methylbenzamide (example compound 96):
  • the reaction mixture was then poured on 500 g of iced water and the product extracted with 500 ml MTBE.
  • the organic layer was recovered and washed with 500 ml of a saturated solution on sodium chloride in water.
  • the organic phase was then dried on sodium sulphate and concentrated to dryness.
  • the HPLC-MS shows the presence of the expected compound as well as of its monomethylated analogue.
  • N-Boc ⁇ -phenyW-piperidinecarboxylic acid 13 mmol N-Boc ⁇ -phenyW-piperidinecarboxylic acid was dissolved in 100 ml ethanol and hydrogenated with hydrogen (6 bars) over 5%-Rh/AI 2 ⁇ 3 at 60° C for 20 h. After filtration and evaporation of solvent, pure crystalline N-Boc-4-cyclohexyl-4- piperidinecarboxylic acid was isolated 4.0 g (100%). Melting point: 156°C.
  • the suspension was diluted with 20 ml MTBE, allowed to stir 30 more minutes and then filtered and washed with MTBE.
  • the solid was dried under high vacuum for 1 h to remove traces of volatile materials yielding 157 mg 4-cyclohexyl-4-piperidinecarboxylic acid dimethylamide hydrochloride (90%) as a white powder.
  • Example 1 1 Synthesis of ⁇ /- ⁇ (2S)-2-(3,4-dichlorophenyl)-4-[4-pyrrolidin-1-yl-4- (pyrrolidin-1-ylcarbonyl)piperidin-1-yl1butyl)- ⁇ /-methylbenzamide (example compound 103)
  • Example 13 Synthesis of ⁇ /- ⁇ (2S)-2-(3,4-dichlorophenyl)-4-[4'-(piperidin-1-ylcarbonyl)- 1 ,4'-bipiperidin-1 '-yl1butyl)- ⁇ /-methylbenzamide (example compound 104)
  • 1'-benzyl-4'-(piperidin-1-ylcarbonyl)-1 ,4'-bipiperidine was obtained by condensation of 2.34 ml (0.00132 mol) of N-benzylpiperidin-4-one, 5.3 ml (0.00536 mol) of piperidine, 1.6 ml ( 0.002 mol) of chloroform and 38 mg of benzyltriethylammonium chloride.
  • reaction mixture was then diluted with 20ml of ethyl acetate and the resulting phase washed twice with 50 ml a 10% aqueous solution of potassium carbonate and once with 50 ml of a saturated sodium chloride water solution.
  • the organic phase was then separated and concentrated to dryness to deliver 206 mg of the title base as a colourless foam in form of the hydrochloride (quantitative yield).
  • Example 13 Synthesis of ⁇ /- ⁇ (2S)-2-(3,4-dichlorophenyl)-4-[4'-(pyrrolidin-1-ylcarbonyl)- 1 ,4'-bipiperidin-1 '-yl1butyl)- ⁇ /-methylbenzamide (example compound 124)
  • Example 14 Alternative synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4- dichlorophenyl)butyl1- ⁇ /-ethyl- ⁇ /-methyl-1 ,4'-bipi-peridine-4'-carboxamide (example compound 95)
  • Example 14 synthesis of 4-( ⁇ [(2S)-2-(3,4-dichlorophenyl)-4- ⁇ 4'-[(dimethylamino)- carbonyli-1 ,4'-bipiperidin-1 '-vDbutylKmethvDaminojcarbonvDphenyl acetate (example compound 5)
  • Table 16 contains analytical data from mass spectroscopy indicating the retention time in relation to the molecular weight observed.
  • the active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate.
  • the paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent.
  • the dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
  • Capsules containing 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid methylamide Capsules with the following composition per capsule were produced:
  • the active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate.
  • the paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent.
  • the dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
  • the active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate.
  • the paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent.
  • the dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
  • the active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate.
  • the paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent.
  • the dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:

Abstract

The present invention relates to novel dual NK2/NK3-antagonists of formula (I) wherein the meaning of X and R1 to R5 is defined in the claims and in the description and also to pharmaceutical compositions comprising these compounds. Furthermore, the invention relates to processes for the preparation of the novel dual NK2/NK3-antagonists and to their uses.

Description

Novel dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation.
Description
The present invention relates to novel dual NK2/NK3-antagonists and also to pharmaceutical compositions comprising these compounds. Furthermore, the invention relates to processes for the preparation of the novel dual NK2/NK3- antagonists.
Neurokinins (NKs) also kown as tachykinins, include the naturally-occurring neuropeptides substance P, neurokinin A and neurokinin B. The tachykinins act as agonists of receptors occurring in larger mammals and humans, such as the neurokinin-1 receptor, the NK-2 receptor and the NK-3 receptor. Artificially prepared compounds which are antagonistic to tachykinin receptors are usually classified according to their relative ability to bind to one or more of the aforementioned three receptor subtypes. In the physiological process the tachykinins play e.g. an important part in the transmission of pain, emesis, neurogenic inflammation, bladder inflammation, inflammatory joint diseases or asthmatic complaints.
A review article about NK receptor antagonists was recently published by
Gerspacher (Progress in Medical Chemistry, 2005, Vol. 43, 49 to 103) giving an overview about recent developments on selective (NK1- or NK2- or NK3-receptor antagonists) and on combined (NK1/NK2-; NK1/NK2/NK3-; and NK2/NK3-) receptor antagonists.
The class of combined NK2/NK3-receptor antagonists appears to be limited by two approaches from GSK and Sanofi. GSK preferred a stepwise modification of the structure of the NK3 selective antagonist talnetant, by the introduction of a variety of substituents at the meta-position of the quinoline moiety of the molecule. A highly effective compound is the following:
Figure imgf000003_0001
Sanofi-Syntheselabo describes in WO 2002/094821 (published November 28, 2002) a series of piperidine-carboxamide derivatives of the following cyclic, non-linear general structure:
Figure imgf000003_0002
Sanofi-Syntheselabo reports a potent NK2-receptor affinity with a Ki value of 0.04 nM and a potent NK3-receptor affinity with a Ki value of 0.04 nM.
However, compounds with a linear core having either a selective NK3-receptor affinity or a combined NK2-/NK3-receptor affinity have not been reported so far.
It was therefore an object of the present invention to provide novel active compounds with a linear core having properties antagonistic to NK2- and/or NK3 tachykinin receptors. These compounds appear particularly suitable for the treatment of a variety of disorders.
Surprisingly, it has now been found that a group of novel linear core-compounds is distinguished by properties antagonistic to tachykinin receptors, in particular to NK2 and/or NK3-receptors. Accordingly, the group of compounds according to the invention appears particularly suitable for the treatment of peripheral disorders in which tachykinins, in particular neurokinin A and/or neurokinin B, participate as transfer agents, for example for the treatment and/or prophylaxis of any pathology where either neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or both neurokinin A and neurokinin B and/or NK2 and NK3-receptors are involved.
In more detail, the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular systems and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases.
In even more detail, the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large- cell lung cancers, diseases of the immune system, bipolar disorders; migraine; pain, anxiety, depression, cognitive disorders, stress- related somatic disorders, psychosis, in particular schizophrenia, mania, schizoaffective disorder and panic disorders.
The subject of the present invention are compounds of general formula I,
Figure imgf000004_0001
wherein
R1 is selected from the group consisting of: alkyl and cycloalkyl;
R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring; R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m NR9R10, and NR7R8; R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and
(CO)mNR9R10;
R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6-membered ring, none of the ring atoms is replaced by carbonyl; R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and physiologically compatible acid addition salts of compounds of Formula I.
Furthermore, another subject of the present invention are pharmaceutical compositions comprising the compounds of Formula I.
Still another subject of the present invention are processes for the preparation of the compounds of Formula I.
Where in the compounds of Formula I or in other compounds described within the scope of the present invention substituents are or contain alkyl and/or alkylene, these may each be straight-chain or branched and possess from 1 to 20 carbon atoms, preferably from 1 to 10 carbon atoms, more preferably from 1 to 7 carbon atoms and even more preferably from 1 to 4 carbon atoms. The most preferred straight-chain alkyl and/or alkylene group is methyl and/or methylene, respectively. The most preferred branched alkyl and/or alkylene group is isopropyl and/or isopropylene, respectively. Where in the compounds of Formula I or in other compounds described within the scope of the present invention substituents are or contain cycloalkyl and/or cycloalkylene, these may possess from 1 to 20 carbon atoms, preferably from 1 to 10 carbon atoms, more preferably from 1 to 7 carbon atoms and even more preferably from 1 to 4 carbon atoms. The most preferred cycloalkyl and/or cycloalkylene groups are cyclopentyl and cyclohexyl and/or cyclopentylene and cyclohexylene, respectively.
Where in the compounds of Formula I or in other compounds described within the scope of the present invention substituents are or contain alkenyl and/or alkenylene, these may each be straight-chain or branched and possess from 2 to 20 carbon atoms, preferably from 2 to 10 carbon atoms, more preferably from 2 to 7 carbon atoms and even more preferably from 2 to 4 carbon atoms. The most preferred alkenyl and/or alkenylene group is ethenyl and/or ethenylene, respectively.
Where substituents in compounds of Formula I are or contain halogen, fluorine, chlorine or bromine are suitable. Chlorine is preferred. Where substituents in compounds of Formula I are or contain carboxyalkyl, -OC(O)alkyl or C(O)Oalkyl are suitable, OC(O)alkyl is preferred.
Where substituents in compounds of Formula I are or contain aryl and/or arylene, monocyclic, bicyclic, tricyclic and tetracyclic aromatic ring systems are suitable. Phenyl is preferred. Where substituents in compounds of Formula I are or contain heteroaryl and/or heteroarylene, monocyclic, bicyclic, tricyclic and tetracyclic aromatic ring systems containing at least one heteroatom such as nitrogen are suitable.
Where substituents in compounds of Formula I are or contain heterocyclic rings, monocyclic, bicyclic, tricyclic and tetracyclic non-aromatic ring systems containing at least one, if not two or three or even four heteroatoms such as nitrogen and/or sulfur and/or oxygen are suitable. A monocyclic ring system is preferred. Nitrogen and/or oxygen are preferred as heteratoms.
Where R7 and R8 and/or R9 and R10 form together a 5- to 7-membered ring and wherein in a particular embodiment, each of these rings independently optionally contain an additional heteroatom, such heteroatom may be selected from nitrogen, oxygen and sulphur, preferably oxygen.
Where in the compounds of Formula I or in other compounds described within the scope of the present invention are or contain alkyl and/or alkylene, alkyl and/or alkylene, aryl and/or arylene, heteroaryl and/or heteroarylene, heterocyclic rings, all these substituents may be further substituted by any of: alkyl, alkenyl, hydroxyl, SH, carbonylalkyl, carboxyalkyl, carbonylaryl, carboxyaryl, carbonylheteroaryl, carboxyheteroyaryl, carbonylheterocyclic ring, carboxyheterocyclic ring, halogen, cyano, oxyalkyl, oxyalkenyl, aryl, heteroaryl, NO2, SO2RH , and SO3RH .
In a preferred embodiment of the present invention, in compounds of Formula I, R1 is methyl.
In another preferred embodiment of the present invention, R3 and R4 are independently selected from the group consisting of: hydrogen, fluoro, chloro, preferably hydrogen or chloro.
In third preferred embodiment of the present invention, in compounds of Formula I X is CR6, R5 is NR7R8, and R6 is (CO)mNR9R10 with m =1.
In another preferred embodiment of the present invention, in compounds X is N, R5 is cycloalkyl substituted with (CO)mNR9R10 and m =1.
In a fourth preferred embodiment of the present invention, in compounds of Formula I, R7 and R8 form together a 6-membered ring or R7 and R8 form together a 6-membered ring substituted by CONR9R10.
In a fifth preferred embodiment of the present invention, in compounds of Formula I R9 and R10 are both methyl, or R9 and R10 form together a 6-membered ring, or R9 and R10 form together a 5-membered ring substituted by carbonyl.
In another preferred embodiment of the present invention, in compounds of Formula I R2 is selected from the group consisting of: C1 to C20 alkyl; C3 to C20 cycloalkyl; C2 to C20 alkenyl;
Figure imgf000007_0001
Figure imgf000008_0001
Figure imgf000008_0002
wherein each of R1 1 to R16 are independently selected from the group consisting of: hydrogen, fluoro, chloro, bromo, hydroxyl, alkoxy, cyano,
N(H)C(O)Oalkyl, aminoalkyl, dialkylamino, OCF3, CF3, carboxyalkyl, S(O)2NH2, phenyl, alkyl, and cycloalkyl; wherein each of R18 and R19 are independently selected from the group consisting of: hydrogen, cyano and aryl; wherein t is 0 or 1 ; wherein each Q is independently selected from the group consisting of: CR1 1 and N; wherein Y is selected from the group consisting of: CH, N and NO; wherein Z is selected from the group consisting of: C-benzyl, NH, N-benzyl, N-alkyl, O and S; wherein each V is independently selected from the group consisting of: N and CR17; and; wherein R17 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, and thioalkyl.
In another preferred embodiment of the present invention, R5 is selected from the group consisting of:
Figure imgf000009_0001
Particular embodiments of the present invention are the following compounds:
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid methylamide; 1 '-[4-(Cyclohexanecarbonyl- methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; Acetic acid 4-{[2-(3,4-dichloro- phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}- phenyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-hydroxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bi-piperidinyl-4'-carboxylic acid dimethylamide; Acetic acid 2-{[2-(3,4-dichloro- phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}- phenyl ester; 1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [(S.δ-difluoro-benzoyO-methyl-aminol-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro- phenyl)-4-[methyl-(naphthalene-1-carbonyl-3-cyano)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2,3,4-trifluoro- benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(1-oxy-pyridine-4-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl- 4'-carboxylic acid dimethylamide; 1 '-[4-[(6-Chloro-pyridine-3-carbonyl)-methyl-amino]-3- (S^-dichloro-phenyO-butyll-II ^'JbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3-
(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-3-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-[(3-Benzyl-2-methylsulfanyl-3H-imidazole-4- carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-oxo-2-phenyl-4H- chromene-3-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Cyclopropanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Cyclopentanecarbonyl-methyl- amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methylamino-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; N-[2-(3,4-Dichloro-phenyl)-4-(4'- dimethylcarbamoyl-II ^'lbipiperidinyl-i '-yO-butyll-N-methyl-phthalamic acid; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(4-methoxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-[(Biphenyl-4-carbonyl)-methyl-amino]-3-(3,4- dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(3,3-diphenyl-propionyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-(3-(3,4-Dichloro-phenyl)-4-{[3-(4-hydroxy-phenyl)- propionyl]-methyl-amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '- {3-(3,4-Dichloro-phenyl)-4-[methyl-(1-methyl-1 H-pyrrole-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [(furan-2-carbonyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethyl- amide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-2-carbonyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2-Biphenyl-4-yl-acetyl)- methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-{[3-(4-Chloro-phenyl)-acryloyl]-methyl-amino}-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro- phenyl)-4-[methyl-(1 H-pyrrole-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(thiophene-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-3-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-
[(I H-indole-S-carbonyO-methyl-aminol-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(2-1 H-indol-3-yl-acetyl)-methyl-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [(I H-indole-δ-carbonyO-methyl-aminol-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyrazine-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(pyridine-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-4-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(4-oxo-4H-chromene-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-sulfamoyl-benzoyl)- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Chloro-3- sulfamoyl-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-1 H-imidazol-4-yl- acetyO-methyl-aminol-butylHI ^'lbipiperidinyW'-carboxylic acid dimethylamide; 1 '-{3- (3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl-acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl- 4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl- acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(2-pyridin-4-yl-acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-[(1-Acetyl-piperidine-4-carbonyl)-methyl-amino]-3- (S^-dichloro-phenyO-butyll-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3- (S^-Dichloro-phenyl^-Imethyl-^etrahydro-pyran^-carbonyO-aminol-butylJ-II ^'lbi- piperidinyl-4'-carboxylic acid dimethylamide; (4-{[2-(3,4-Dichloro-phenyl)-4-(4'- dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl)-carbamic acid tert-butyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl-methoxy}- benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-(3-(3,4-Dichloro-phenyl)-4-{[2-(2,4-di{trifluoromethyl}-phenyl)-acetyl]-methyl-amino}- butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-(3-(3,4-Dichloro-phenyl)-4- {[2-(2,6-dihydroxy-pyrimidin-4-yl)-acetyl]-methyl-amino}-butyl)-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 4-{[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl- [1 ,4']bipiperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-piperidine-1 -carboxylic acid tert-butyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-imidazole-4-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; (1-{[2-(3,4-Dichloro-phenyl)-4-(4'- dimethylcarbamoyl-II ^'lbipiperidinyl-i '-yO-butyll-methyl-carbamoyl^-phenyl-ethyl)- carbamic acid tert-butyl ester; [2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-
[1 ,4']bipiperidinyl-1 '-yl)-butyl]-methyl-carbamic acid tert-butyl ester; 1 '-{3-(3,4-Dichloro- phenyl)-4-[(furazan-3-carbonyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,2-difluoro-benzo[1 ,3]dioxole-5- carbonyO-methyl-aminol-butylJ-II ^'lbipiperidinyl^'-carboxylic acid dimethylamide; V- {3-(3,4-Dichloro-phenyl)-4-[methyl-(1 H-pyrrole-3-carbonyl)-amino]-butyl}- [1 ,4']bipipeιϊdinyl-4'-carboxylic acid diethylamide; 1 '-(3-(3,4-Dichloro-phenyl)-4-{[3-(4- fluoro-phenylJ-S-methyl-isoxazole^-carbo-nyll-methyl-aminoJ-butylJ-II ^'lbipiperidinyl- 4'-carboxylic acid diethylamide; 1 '-(3-(3,4-Dichloro-phenyl)-4-{[5-(4-methoxy-phenyl)- oxazole-4-carbonyl]-methyl-amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethyl- amide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1-phenyl-1 H-[1 ,2,3]triazole-4- carbonyO-aminoJ-butylHI ^'JbipiperidinyW'-carboxylic acid dimethylamide; 1 '-[4- [(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperi- dinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl- benzoIbJthiophene^-carbonyO-aminol-butylJ-II ^'lbipiperidinyl^'-carboxylic acid dimethylamide; 1 '-[4-[(3,5-Bis-trifluoromethyl-benzoyl)-methyl-amino]-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2-Bromo- benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-fluoro-benzoyl)-methyl-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[3-(3,4-Dichloro-phenyl)-4- (methyl-pentafluorobenzoyl-amino)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,6-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2,4-Dichloro-benzoyl)-methyl- amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2,6-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-
[methyl-(2-trifluoromethyl-benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3- fluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethyl- amide; 1 '-[4-[(3-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3,4-Dichloro-benzoyl)-methyl- amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-methoxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(3-trifluoromethyl-benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4- methoxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-trifluoromethyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4- methyl-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethyl- amide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,2-dimethyl-propionyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[3-(3,4-Dichloro-phenyl)-4- (methyl-phenylacetyl-amino)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-phenyl-cyclopropanecarbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Cyano-benzoyl)-methyl- amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-1 -carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Cyano-naphthalene-1- carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-phenyl-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid ethyl-methyl-amide; N-{2-(3,4-Dichloro- phenyl)-4-[4-(1-dimethylcarbamoyl-cyclohexyl)-piperazin-1-yl]-butyl}-N-methyl-benz- amide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-2- carboxylic acid dimethylamide; 1-[4-[(3-Cyano-naphthalene-1-carbonyl)-methyl-amino]- 3-(3,4-dichloro-phenyl)-butyl]-4-pyrrolidin-1 -yl-piperidine-4-carboxylic acid dimethylamide; 1-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-4-pyrrolidin-1-yl- piperidine-4-carboxylic acid dimethylamide; N-[4-[4-(Cyclopropylmethyl-propionyl- amino)-piperidin-1-yl]-2-(3,4-dichloro-phenyl)-butyl]-N-methyl-benzamide; N-{2-(3,4-
Dichloro-phenyl)-4-[4-(isopropyl-propionyl-amino)-piperidin-1-yl]-butyl}-N-methyl- benzamide; N-{2-(3,4-Dichloro-phenyl)-4-[4-(phenyl-propionyl-amino)-piperidin-1-yl]- butyl}-N-methyl-benzamide; N-[4-[4-(Butyl-propionyl-amino)-piperidin-1-yl]-2-(3,4- dichloro-phenyl)-butyl]-N-methyl-benzamide; N-[4-[4-(Butyl-cyclopropanecarbonyl- amino)-piperidin-1-yl]-2-(3,4-dichloro-phenyl)-butyl]-N-methyl-benzamide; N-[4-[4-
(Butyl-cyclohexanecarbonyl-amino)-piperidin-1-yl]-2-(3,4-dichloro-phenyl)-butyl]-N- methyl-benzamide; N-[4-[4-(Benzoyl-butyl-amino)-piperidin-1-yl]-2-(3,4-dichloro- phenyl)-butyl]-N-methyl-benzamide; N-(2-(3,4-Dichloro-phenyl)-4-{4-[(4-methoxy-butyl)- propionyl-amino]-piperidin-1-yl}-butyl)-N-methyl-benzamide; N-[4-{4- [Cyclopropanecarbonyl-(4-methoxy-butyl)-amino]-piperidin-1-yl}-2-(3,4-dichloro- phenyl)-butyl]-N-methyl-benzamide; N-[4-{4-[Cyclohexanecarbonyl-(4-methoxy-butyl)- amino]-piperidin-1-yl}-2-(3,4-dichloro-phenyl)-butyl]-N-methyl-benzamide; N-[4-{4-
[Benzoyl-(4-methoxy-butyl)-amino]-piperidin-1-yl}-2-(3,4-dichloro-phenyl)-butyl]-N- methyl-benzamide; N-[4-{4-[cyclohexyl(propionyl)amino]piperidin-1-yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide; N-[4-{4-[cyclohexyl(cyclopropylcarbonyl)- amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; N-[4-{4-[cyclo- hexyl(cyclohexylcarbonyl)amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-N-methyl- benzamide; N-[4-{4-[benzoyl(cyclohexyl)amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)- butyl]-N-methylbenzamide; N-[2-(3,4-dichlorophenyl)-4-{4-[(1-methylpiperidin-4-yl)- (propionyl)amino]piperidin-1-yl}butyl]-N-methylbenzamide; N-[4-{4-[(cyclopropyl- carbonyl)(1-methylpiperidin-4-yl)amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-N- methylbenzamide; N-[4-{4-[(cyclohexylcarbonyl)(1-methylpiperidin-4-yl)amino]piperidin- 1-yl}-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; N-{1-[4-[benzoyl(methyl)amino]- 3-(3,4-dichlorophenyl)butyl]piperidin-4-yl}-N-(1-methylpiperidin-4-yl)benzamide; N-{2- (3,4-Dichloro-phenyl)-4-[4'-(pyrrolidine-1-carbonyl)-[1 ,4']bipiperidinyl-1 '-yl]-butyl}-N- methyl-benzamide; 1-[4-[(3-Cyano-naphthalene-1-carbonyl)-methyl-amino]-3-(3,4- dichloro-phenyl)-butyl]-4-(2-oxo-pyrrolidin-1-yl)-piperidine-4-carboxylic acid dimethyl- amide; S-Cyano-naphthalene-i-carboxylic acid {2-(3,4-dichloro-phenyl)-4-[4'- (piperidine-1-carbonyl)-[1 ,4']bipiperidinyl-1 '-yl]-butyl}-methyl-amide; 1 '-[4-(Benzoyl- methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid di- propylamide; 1-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-4-morpholin -4-yl-piperidine-4-carboxylic acid dimethylamide; 1-[4-(Benzoyl-methyl-amino)-3-(3,4- dichloro-phenylj-butyl^-pyrrolidin-i-yl-piperidine^-carboxylic acid isopropyl-methyl- amide; N-{2-(3,4-Dichloro-phenyl)-4-[4-(piperidine-1-carbonyl)-4-pyrrolidin-1-yl- piperidin-1 -yl]-butyl}-N-methyl-benzamide; 1 -[4-(Benzoyl-methyl-amino)-3-(3,4- dichloro-phenylj-butyll^-pyrrolidin-i-yl-piperidine^-carboxylic acid diethylamide; N-{2- (3,4-Dichloro-phenyl)-4-[4-(morpholine-4-carbonyl)-4-pyrrolidin-1-yl-piperidin-1-yl]- butyl}-N-methyl-benzamide; and physiologically compatible acid addition salts of these compounds.
Particularly preferred are the following compounds:
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid methylamide; 1 '-[4-(Cyclohexanecarbonyl- methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; Acetic acid 4-{[2-(3,4-dichloro- phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}- phenyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-hydroxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bi-piperidinyl-4'-carboxylic acid dimethylamide; Acetic acid 2-{[2-(3,4-dichloro- phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}- phenyl ester; 1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dicriloro-prienyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [(S.δ-difluoro-benzoyO-methyl-aminol-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro- phenyl)-4-[methyl-(naphthalene-1-carbonyl-3-cyano)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; V-{3-(3,4- Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2,3,4-trifluoro- benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(6- Chloro-pyridine-3-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(pyridine-3-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Cyclopentanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-
[methyl-(2-methylamino-benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; N-[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl- 1 '-yl)-butyl]-N-methyl-phthalamic acid; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methoxy- benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-(3- (3,4-Dichloro-phenyl)-4-{[3-(4-hydroxy-phenyl)-propionyl]-methyl-amino}-butyl)-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(1-methyl-1 H-pyrrole-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(naphthalene-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 H-pyrrole-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [(furan^-carbonyO-methyl-aminol-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(thiophene-3-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-indole-5-carbonyl)-methyl-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(pyridine-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-4-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(4-oxo-4H-chromene-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-sulfamoyl-benzoyl)- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Chloro-3- sulfamoyl-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl- acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl-acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-4-yl- acetyO-aminoJ-butylJ-II ^'lbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(tetrahydro-pyran-4-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; (4-{[2-(3,4-Dichloro-phenyl)-4-(4'- dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl)-carbamic acid tert-butyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl-methoxy}- benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-(3- (3,4-Dichloro-phenyl)-4-{[2-(2,4-di{trifluoromethyl}-phenyl)-acetyl]-methyl-amino}-butyl)- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(2,2- difluoro-benzoII .Sldioxole-δ-carbonyO-methyl-aminol-butylJ-II ^'lbipiperidinyW- carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1- phenyl-1 H-[1 ,2,3]triazole-4-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2-Bromo-benzoyl)- methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(2,6- difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1'-[4-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4- [methyl-(2-trifluoromethyl-benzoyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methyl-benzoyl)-amino]-butyl}- [1 ,4']bipipeιϊdinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3- fluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-[4-[(3-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3- methoxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(3-trifluoromethyl-benzoyl)- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro- phenyl)-4-[(4-methyl-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Cyano-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Cyano-naphthalene-1- carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-phenyl-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid ethyl-methyl-amide; N-{2-(3,4-Dichloro- phenyl)-4-[4-(1-dimethylcarbamoyl-cyclohexyl)-piperazin-1-yl]-butyl}-N-methyl- benzamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-2-carboxylic acid dimethylamide; 1-[4-[(3-Cyano-naphthalene-1- carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-4-pyrrolidin-1-yl-piperidine-4- carboxylic acid dimethylamide; 1-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-4-pyrrolidin-1-yl-piperidine-4-carboxylic acid dimethylamide; and physiologically compatible acid addition salts of these compounds.
Most preferred compounds of the present invention are the following:
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4- dichloro-phenyO-butylHI ^'JbipiperidinyW-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; Acetic acid 4-{[2-(3,4-dichloro-phenyl)-4-(4'- dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester; 1 '- {3-(3,4-Dichloro-phenyl)-4-[(4-hydroxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide; Acetic acid 2-{[2-(3,4-dichloro-phenyl)-4- (4'-dimethylcarbamoyl-[1 ,4']bi-piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester; 1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(3,5- difluoro-benzoyO-methyl-aminol-butylHI ^'lbipiperidinyW'-carboxylic acid diethylamide; 1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide; 1 '-{3-(3,4-Dichloro- phenyl)-4-[methyl-(naphthalene-1-carbonyl-3-cyano)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1'-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; V-{3-(3,4- Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-[(6-Chloro-pyridine-3-carbonyl)-methyl-amino]-3- (S^-dichloro-phenyO-butylHI ^'JbipiperidinyW-carboxylic acid dimethylamide; 1 '-[4- (Cyclopentanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl- 4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(pyridine-2-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl- acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4- Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl-acetyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl- methoxy}-benzoyl)-methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1-phenyl-1 H-
[1 ,2,3]triazole-4-carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Cyano-naphthalene- 1-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 -[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4- dichloro-pheny^-butyll^-pyrrolidin-i-yl-piperidine^-carboxylic acid dimethylamide; and physiologically compatible acid addition salts of these compounds.
The compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula Il
Figure imgf000019_0001
wherein R1 to R4 have the above meanings, with a compound of formula
Figure imgf000019_0002
wherein R5 has the above meaning, to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt.
Alternatively, the compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula III
Figure imgf000019_0003
wherein R5 has the above meaning, with a compound of general formula IV
Figure imgf000019_0004
wherein R1 , R3 and R4 have the above meanings, to give a compound of the general formula V,
Figure imgf000019_0005
The compound of general formula V is then hydrolyzed in an acidic medium to give a compound of general formula Vl,
Figure imgf000020_0001
wherein R1 and R3 to R5 have the above meanings. The compound of general formula Vl is then reacted with a compound of formula VII
O
Λ VII
R2 Cl
wherein R2 has the above meaning, to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt.
Alternatively, the compounds of Formula I and their acid addition salts may be prepared by reacting a compound of the general Formula X
Figure imgf000020_0002
wherein Q is selected from the group consisting of: halogen, preferably, bromo or iodo; and methylsulfonyl; with a compound of formula III
Figure imgf000020_0003
to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt. The compounds of Formula Il can be prepared by reacting a compound of formula VII
Figure imgf000021_0001
with a compound of formula VII
R2 A Cl V,, to give a compound of formula IX
Figure imgf000021_0002
The compound of formula IX is then oxidized to give a compound of formula II.
The compounds of Formula III are well-known and can be prepared as disclosed in any of J. Med. Chem. 1964, p. 619 (van de Westeringh); WO02/094821
(Sanofi); J. Org. Chem. 1980, 45, p. 3671 (J. T. Tai); J. Med. Chem. 1974, 9, p. 424 (B.
Devaux); J. Med. Chem. 2002, 45, p. 3972 (J. T. Albert). A reaction scheme for the preparation of compounds of formula Il is giving in example 37.
The compounds of Formula IV can be prepared in a similar manner as suggested for compounds of Formula II, by selecting an appropriate R2.
The compounds of Formula VII are known per se or can be prepared by the person skilled in the art from known compounds in known manner.
The compounds of Formula X can be prepared by reacting a compound of the general Formula IX
Figure imgf000022_0001
with HHalogen, preferably HBr or HI to deliver compounds of Formula X wherein Q is a halogen, preferably bromo or iodo, or, alternatively, with methanesulfonylchloride to deliver compounds of Formula X wherein Q is methylsulfonyl
Figure imgf000022_0002
The compounds of Formula I may be isolated from the reaction mixture and purified in known manner. Acid addition salts may be converted into the free bases in conventional manner, and these may if desired be converted in known manner into physiologically compatible acid addition salts. Physiologically compatible salts of compounds of Formula I are their conventional salts with inorganic acids, for example sulphuric acid, phosphoric acids or hydrohalic acids, preferably hydrochloric acid, or with organic acids, for example lower aliphatic monocarboxylic, dicarboxylic or tricarboxylic acids such as maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, or with sulphonic acids, for example lower alkanesulphonic acids such as methanesulphonic acid or trifluoromethanesulphonic acid, or benzenesulphonic acids optionally substituted in the benzene ring by halogen or lower alkyl, such as p- toluenesulphonic acid.
The compounds of Formula I contain in the γ-position to the ring nitrogen atom in the 4-position of the piperidine or piperazine ring, respectively, an asymmetrical carbon atom, namely the carbon atom *C bearing the phenyl ring substituted by R3 and R4. Hence, the compounds of Formula I may be present in several stereo isomeric forms. The present invention covers both the mixtures of optical isomers and the isomerically pure compounds of Formula I. Preferred are compounds of Formula I in which the carbon atom *C bearing the phenyl ring substituted by R3 and R4 is in the S- configuration. If mixtures of optical isomers of the starting compound, for example of the compounds of Formula Il or the compounds of Formula IV, are used in the synthesis of the compounds of Formula I, the compounds of Formula I are also obtained in the form of mixtures of optical isomers. Departing from stereochemical^ uniform forms of the starting compound, stereochemical^ uniform compounds of Formula I can also be obtained. The stereochemical^ uniform compounds of Formula I can be obtained from the mixtures of optical isomers in known manner, for example by chromatographic separation on chiral separating materials or by reaction with suitable optically active acids, for example tartaric acid or 10-camphorsulphonic acid, and subsequent separation into their optically active antipodes by fractional crystallisation of the diastereomeric salts obtained.
The compounds of Formula I and their acid addition salts have properties which are antagonistic to tachykinin receptors and are therefore suitable for the treatment of pathological conditions in larger mammals, particularly humans, in which tachykinins are involved as transfer agents. The group of compounds according to the invention is distinguished by a particularly beneficial action profile which is characterised by a high selectivity to NK2 and/or NK3-receptors. Furthermore, the group of compounds according to the invention is distinguished by good compatibility even over prolonged periods of administration, and by comparatively good oral availability. Owing to their action profile, the compounds of Formula I are suitable in particular for inhibiting processes in which tachykinins, such as neurokinin A, which bind to NK2-receptors, and/or neurokinin B, which which to NK3-receptors are involved. Owing to the action which is advantageously directed at the peripheral region, the compounds of Formula I are suitable in particular for the treatment and/or prophylaxis of any pathology where either neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or both neurokinin A and neurokinin B and/or NK2 and NK3-receptors are involved. Some compounds of the present invention and in particularly those, wherein R2 is a cyano-substituted naphthalene ring system are also suitable for inhibiting processes in which tachykinins, such as substance P, which bind to NK1 -receptors, are involved. Owing to the action which is advantageously directed at the peripheral region, compounds of Formula I wherein R2 is a cyano-substituted naphthalene ring system, are suitable in particular for the treatment and/or prophylaxis of any pathology where substance P and/or NK1 -receptors, or neurokinin A and/or NK2-receptors, or neurokinin B and/or NK3-receptors, or any combination of two or all three substance P, neurokinin A and neurokinin B and/or NK1 , NK2 and NK3-receptors are involved.
In more detail, the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular system and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases.
In even more detail, the compounds of the present invention appear particularly suitable for the treatment and/or prophylaxis of pathologies of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large- cell lung cancers, diseases of the immune system, bipolar disorders; migraine; pain, anxiety, depression, cognitive disorders, stress- related somatic disorders, psychosis, in particular schizophrenia, mania, schizoaffective disorder and panic disorders.
The functional disorders in the gastrointestinal tract which can be treated by the compounds according to the invention include in particular the disorders of the lower intestinal tracts known under the name "irritable bowel syndrome" (= IBS). Typical symptoms for the diagnosis of IBS are described, for example, in W. G. Thompson et al., Gastroenterology International 2 (1989) 92-95 or in W.G. Thompson et al., GUT 45/II (1999) II43-II47, and are generally known among experts by the term "Rome Criteria". The essential symptoms of IBS accordingly include pains in the lower abdomen, which appear to be due to hypersensitivity of the visceral afferent nervous system, and anomalies in bowel movement, such as constipation, diarrhoea or alternating constipation and diarrhoea. Further inflammatory disorders in the gastrointestinal tract which can be beneficially influenced by the group of compounds according to the invention are for example the inflammatory disorders in the small intestine and large intestine regions usually covered by the term "inflammatory bowel disease" (= IBD), for example ulcerative colitis or Crohn's disease. Owing to their action mechanism, the compounds according to the invention furthermore appear suitable for the treatment of other disorders in which tachykinins and in particular neurokinin A are involved as transfer agents. These disorders include for example neurogenic inflammation, inflammatory joint diseases such as rheumatic arthritis, asthmatic complaints, allergic disorders, disorders of immune regulation, bladder inflammation or also functional dyspepsia.
Another advantage of the compounds of the present invention is the synergistic effect between the NK2- and NK3-profile.
Another advantage of the compounds of the present invention is their very balanced combined NK2- and NK3-profile.
Description of the pharmacological test methods
The example numbers given for the compounds of Formula I used as test substances in the pharmacological tests given below relate to the preparation examples described below.
1. Determination of the binding potency of the test substances to NK1 -receptors in vitro
The affinity of test compounds for NK1 -receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site. The tests were performed at Solvay Pharmaceuticals, Weesp, The Netherlands.
The radiolabel used in this assay is [3H]-Substance P. Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK1 -receptor was stably expressed. Membranes were incubated with [3H]- Substance P in the absence or presence of test compounds at different concentrations, diluted in a buffer system. Separation of bound radioactivity from free radioactivity was done by filtration through glass fiber filters (Packard GF/B) with several washings with ice-cold buffer solution. Bound radioactivity was measured with a liquid scintillation counter (total binding). Unspecific binding was determined by incubation with an excess (1 μmol/l) of unlabeled Substance P.
Specific binding is obtained by subtraction of the unspecific from the total binding.
Radioactivity of the specific binding was plotted against the concentration of the test compound and IC50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated. The inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi). The pKi value describes the potency of a test compound to bind to a receptor.
Table 1 : Binding potency of the test substances to NK1 -receptors in vitro
Figure imgf000026_0002
Figure imgf000026_0001
For the compounds of all examples, the affinity to human NK1-receptors was determined in each case by at least three measurements of the test substances in concentration series of 1 (H> to 10' "O mol/l. The average result of all measurements is listed above. The compounds of Example No. 1 , 4, 8 to 1 1 , 14, 15, 24, 49, 55, 56, 65, 70, 80, 82, 83, 89, 92, 93, 98, 101 to 103, 105, 108, 1 16, and 125 to 127 exhibited pKi values of at least 7.0 in this test model. The compounds of Example No. 1 1 , 93, 98, 101 , 102 and 126 exhibited pKi values of at least 8.0. 2. Determination of the binding potency of the test substances to NK2-receptors in vitro
The affinity of test compounds for NK2-receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site.
The radiolabel used in this assay is [3H]-SR 48968 (saredutant). Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK2-receptor was stably expressed. Membranes were incubated with [3H]-saredutant in the absence or presence of test compounds at different concentrations, diluted in a buffer system. Separation of bound radioactivity from free radioactivity was done by filtration through glass fiber filters (Packard GF/B) with several washings with ice-cold buffer solution. Bound radioactivity was measured with a liquid scintillation counter (total binding). Unspecific binding was determined by incubation with an excess (0.1 μmol/l) of unlabeled saredutant.
Specific binding is obtained by subtraction of the unspecific from the total binding.
Radioactivity of the specific binding was plotted against the concentration of the test compound and IC50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated. The inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi). The pKi value describes the potency of a test compound to bind to a receptor.
Table 2: Binding potency of the test substances to NK2-receptors in vitro
Figure imgf000028_0001
Figure imgf000029_0001
For the compounds of Example No. 1 to 47, 49 to 53, 55, 56, 58, 59, 61 , 63 to 104 and 124 to 127, the affinity to human NK2-receptors was determined in each case by at least three measurements of the test substances in concentration series of 10~6 to 10'"O mol/l. The average result of all measurements is listed above. All the aforementioned test substances exhibited pKi values of at least 7.0 in this test model. The compounds of Example No. 1 to 16, 18, 19, 23 to 26, 29 to 31 , 35 to 38, 41 , 43 to 47, 49, 55, 63, 67, 68, 71 , 72, 74, 75, 77 to 80, 82, 83, 87, 91 , 94 to 105, 108, 1 16, 124, 126 and 127 exhibited pKi values of at least 8.0. The compounds of Example No. 1 , 2, 4 to 6, 8, 9, 13 to 16, 95, 104 and 124 exhibited pKi values of at least 9.0.
3. Determination of the binding potency of the test substances to NK3-receptors in vitro
The affinity of test compounds for NK3-receptors can be determined by measuring the ability of the test compound to displace a radiolabeled ligand from its specific binding site. The radiolabel used in this assay is [3H]-SR 142801 (osanetant). Receptors were obtained from membrane preparations of CHO-cells (Chinese Hamster Ovary cells), in which the human NK3-receptor was stably expressed. Membranes were incubated with [3H]-osanetant in the absence or presence of test compounds at different concentrations, diluted in a buffer system. Separation of bound radioactivity from free radioactivity was done by filtration through glass fiber filters (Packard GF/B) with several washings with ice-cold buffer solution. Bound radioactivity was measured with a liquid scintillation counter (total binding). Unspecific binding was determined by incubation with an excess (1 μmol/l) of unlabeled osanetant.
Specific binding is obtained by subtraction of the unspecific from the total binding.
Radioactivity of the specific binding was plotted against the concentration of the test compound and IC50 values, i.e. the concentration of test compound by which 50% of the radioligand is displaced, were calculated. The inhibition constant (Ki) was calculated according to the Cheng-Prusoff equation, and listed as its negative logarithmic value (pKi) The pKi value describes the potency of a test compound to bind to a receptor.
Table 3: Binding potency of the test substances to NK3-receptors in vitro
Figure imgf000031_0001
Figure imgf000031_0002
For the compounds of Example No. 1 , 3 to 7, 9 to 16, 18, 19, 21 to 23, 25, 26, 29 to 33, 36 to 41 , 43 to 47, 49 to 57, 60, 63 to 87, 89 to 91 , 95, 97 to 104, and 124 to 126 the affinity to human NK3-receptors was determined in each case by at least three measurements of the test substances in concentration series of 10'^ to 10' "O mol/l. The average result of all measurements is listed above. All the aforementioned test substances exhibited pKi values of at least 7.0 in this test model. The compounds of Example No. 1 , 3 to 10, 14, 15, 18, 23, 36, 43, 49 to 51 , 53 to 56, 67, 68 and 83 exhibited pKi values of at least 8.0.
4. Functional cellular tests of the NK1-, NK2- and NK3-antagonism
Functional cellular tests of the antagonistic effect of the compounds of the present invention on the human tachykinin receptors were performed in CHO cells expressing the recombinant human NK1 , NK2 or NK3-receptor. In these tests the inhibition of ligand-induced increase in mobilization of intracellular calcium and inhibition of ligand-induced phosphorylation of mitogen activated protein kinase (MAPK) were determined, which can be used as a measure of functional activity of tachykinin-antagonists. Additionally, the antagonistic properties of reference compounds on the different tachykinin receptors were characterized for comparison.
The effects of test compounds were assessed using Chinese hamster ovary
(CHO) fibroblast cells, stably expressing cloned human NK1 , NK2 or NK3-receptors.
The NK receptor is coupled to Gq. The activation of the Gq protein by ligand binding to the receptor leads to a mobilization of intracellular calcium and phosphorylation of
MAPK. Both systems were used to determine functional effects of the test compounds.
Ca2+ measurements using FLIPR for NK1 and NK2 activity
For tests, cells were seeded 24 hours prior to the experiment into black 96-well microplates. The cell density was 2.2x104 cells/well. All steps were done under sterile conditions. In order to observe changes in intracellular calcium levels, cells were loaded with a calcium-sensitive dye. This dye (FLUO-4, from Molecular Probes) excites at 488 nm, and emits in the 500 nm to 560 nm range, only if a complex with calcium is formed. For the dye loading the growth-medium was aspirated out of the well without disturbing the confluent cell layer and 100 μl loading medium (HBSS, 4 μM FLUO-4, 0.005% (w/v) pluronic acid, 2.5mM probenecid, 20 mM HEPES, pH 7.4) was dispensed into each well using an automatic pipettor system (Multidrop, Labsystems). Pluronic acid was added to increase dye solubility and dye uptake into the cells, whereas probenecid, an anion exchange inhibitor, was added to the loading medium to increase dye retention in the cells. The cells were incubated in a 5% CO2 incubator at 37 0C for 40 minutes. After dye loading, the cells were washed three times with wash- buffer (HBSS, 2.5 mM probenecid, 20 mM HEPES, pH 7.4) to reduce basal fluorescence. In the last washing step the buffer was aspirated and replaced with 100 μl washing buffer. For the antagonism screening mode 50 μl of the compound (final concentration ranges from 10 μM to 1.4 nM) were applied 7 min prior to addition of substance P (final concentration: 10'8 M; NK1 agonist) or NKA (final concentration: 10'7 M; NK2 agonist). The FLIPR setup parameters were set to 0.4 sec exposure length, filter 1 , 50 μl fluid addition, pipettor height at 125 μl, dispense speed 40 μl/sec without mixing. Maximal fluorescence changes were obtained using the statistic function of the FLIPR software, and data plotted using GraphPad Prism 4. All points were expressed as a percentage inhibition of the control agonist. IC50 values were determined using sigmoidal dose-response curve fitting. Antagonist potencies (pA2) values were calculated using equation:
PA2 = -log (IC50/(1 + [L] / EC50)),
in which the IC50 of the test compound was obtained from concentration-effect relationships, [L] is the concentration of the agonist (substance P for NK-| test, NKA for
NK2 test, NKb for NK3 test), and the EC50 is the potency of the agonist at the respective human cloned NK receptor (EC50 substance P: 10"96 M; EC50 NKA: 10"8 8 M, EC50 NKB: 10"88 M). The results are summarized in tables 4 and 5:
Table 4: pA2 data for NK1 :
Figure imgf000034_0003
Figure imgf000034_0001
Table 5: pA2 data for NK2
Figure imgf000034_0004
Figure imgf000034_0002
Ca2+ measurements using aequorin for NK3 activity NK3 antagonism was measured in a cell line expressing the human NK3 receptor and mitochondrially targeted apoaequorin. In this system, cells expressing apoaequorin are incubated with coelenterazine, which is the chromophore co-factor of aequorin. Upon incubation of the cells with senktide, a potent agonist on NK3, intracellular calcium concentration increases. Traces of free calcium lead to a concentration dependent activation of the catalytic activity of aequorin, which oxidizes coelenterazine and yields apoaequorin, coelenteramide, CO2 and light (λmax=469nm). Once the photon has been emitted, the complex must dissociate and the apoaequorin must recombine with the co-factor before the complex can emit another photon. Thus, in this system, measurements of luminescence (light emission) following senktide addition reflects an increase in intracellular calcium due to activation of NK3 receptors.
For the test, cells were grown to confluency and harvested with complexon (5mM EDTA in PBS). Cells were centrifugated and resuspended in DMEM/F-12 (nutrient mixture according to Ham) without phenolred, supplemented with 10% FCS to a density of 5x106 cells/ml. In order to load the cells, coelenterazine was added to a final concentration of 5μM and cells were stirred at room temperature for 4 hours. Loaded cells were diluted in DMEM/F12 without phenolred and supplements to a density of 2.8x105 cells/ml, pre-heated to 37°C, and stirred for 60min at room temperature. For the antagonism screening mode 15μl of the cell suspension were added to 85μl of the compound (final concentration ranges from 4.5nM to 10μM) in white 96-well plates. After an incubation time of 20 min 50μl senktide (final concentration of 5x10-8M) were applied and chemoluminescence was measured immediately for 20 seconds using the Microlumat (Berthold). All points were expressed as a percentage inhibition of the control agonist. IC50 values were determined using sigmoidal dose-response curve fitting of GraphPad Prism 4. Antagonist potencies (pA2) values were calculated using equation:
pA2 = plC50 + log [(L / EC50)-1],
in which the plC50 is the negative logarithm of the IC50 value of the test compound that was obtained from concentration-effect relationships, L is the concentration of senktide and EC50 its potency at the human cloned NK3 receptor (EC50 senktide: 10- 8.8M). Table 6: pA2 data for NK3
Figure imgf000036_0002
5. Determination of functional NK1 -receptor antagonism of test compounds in tissue isolated from guinea pigs.
The NK1 -antagonistic action of test compounds was tested in aortic ring preparations isolated from guinea pigs. The preparations were kept in an oxygenated nutrient solution kept at 37°C. For measuring contraction of the circular vascular muscle, the preparations were fixed to a hook and connected to force displacement transducers. Contractions/relaxations were recorded on a pen recorder. The preparations were given a medium tonus by addition of phenylephrine.
The NK1 -receptors were stimulated with the NK1 -receptor agonist Substance P, causing a relaxation of the muscular tone. Before (predrug) and after the administration of the test compound such relaxations were measured and quantified in percent of the predrug relaxation. 2-3 concentrations of the test compound were applied showing the inhibition of the receptor stimulation concentration dependently. The concentration of half-maximal inhibition (IC50) and its negative logarithm plC50= - log (IC50) was calculated. The plC50 value indicates the inhibitory potency of the test compounds to the NK1 -receptor. Table 7: Functional NK1 -antagonism of the test substances on isolated guinea pig tissue
Figure imgf000037_0001
6. Determination of functional NK2-receptor antagonism of test compounds in tissue isolated from guinea pigs.
The NK2 antagonistic action of test compounds was tested in gall bladder preparations isolated from guinea pigs. The preparations were kept in an oxygenated nutrient solution kept at 37°C. For measuring contraction of the gall bladder muscle, the preparations were fixed to a hook and connected to force displacement transducers. Contractions were recorded on a pen recorder. The NK2-receptors were stimulated with the NK2-receptor agonist neurokinin A, causing a contraction of the muscle. Before (predrug) and after the administration of the test compound such contractions were measured and quantified in percent of the predrug contraction. 2-3 concentrations of the test compound were applied showing the inhibition of the receptor stimulation concentration dependently. The concentration of half-maximal inhibition (IC50) and its negative logarithm plC5o= -log (IC5o) was calculated. The plC5o value indicates the inhibitory potency of the test compounds to the NK2-receptor.
Table 8: NK-2-receptor-antagonistic effectiveness of the test substances of Formula I on the guinea pig gall bladder in vitro
Figure imgf000037_0002
7. Determination of functional NK3-receptor antagonism of test compounds in tissue isolated from guinea pigs. The NK3-antagonistic action of test compounds was tested in ileal preparations isolated from guinea pigs. The preparations were kept in an oxygenated nutrient solution kept at 37°C. For measuring contraction of the longitudinal muscle of the ileum, the preparations were fixed to a hook and connected to force displacement transducers. Contractions were recorded on a pen recorder.
The NK3-receptors were stimulated with the NK3-receptor agonist [MePhe7]- neurokinin B, causing a contraction of the muscle. Before (predrug) and after the administration of the test compound such contractions were measured and quantified in percent of the predrug contraction. 2-3 concentrations of the test compound were applied showing the inhibition of the receptor stimulation concentration dependently. The concentration of half-maximal inhibition (IC50) and its negative logarithm plC50= - log (IC50) was calculated. The plC50 value indicates the inhibitory potency of the test compounds to the NK3-receptor.
Table 9: Functional NK3-antagonism of the test substances on isolated guinea pig tissue
Figure imgf000038_0001
8. Determination of the NK3-receptor-antagonistic effectiveness of the test substances in vivo (reduction of body temperature in gerbils with senktide- induced hypothermia)
NK3 agonists reduce the body temperature of gerbils. The senktide-induced hypothermia can be antagonized by administering compounds with NK3-antagonistic properties. Measuring the level of hypothermia is indicative for the degree of activity of the test compounds. The own effect of the tested compound is assessed in the same experiment to exclude an additional hyperthermic effect.
Male gerbils with a body weight between 60 to 90 g are housed in groups under normal day-night rhythm and under constant environmental temperature (room temperature: 21 ±2 0C) with a constant relative humidity level (50±10%). Water and food are freely available. Reference agonist: Senktide 0.03 mg/kg sc. Antagonists: see example compounds in table X.
Per series of experiments, one condition is always the vehicle/vehicle group to determine the normal body temperature and one condition is always the vehicle/senktide group to determine the senktide induced hypothermia (=100%). The animals are weighted and marked 60 minutes prior to the agonist administration. For oral (po) testings, the test compounds are administered at t = -60 minutes. For parenteral or subcutaneous (i por sc, resp.) administration, at t = -30 minutes. At t = 0 minutes the agonist Senktide is administered (sc). At t = 15 minutes the temperature is measured orally, and registered with a 0.1 0C accuracy after a 10 second reading. This way, animals are measured every 60 sec.
Using the Dunett's test, the vehicle/vehicle group is used as reference for the analysis of the own effect; whereas the vehicle/senktide group is used for comparison for the interaction test (i.e. example compounds/senktide groups).
Table 10: Inhibition of temperature increase at t = 60 minutes after oral (po) administration
Figure imgf000039_0001
Table 1 1 : Inhibition of temperature increase at a dose of 10 mg/kg after parenteral (ip) administration
Figure imgf000039_0002
9. Determination of the NK-3-receptor-antagonistic effectiveness of the test substances in vivo (reduction of blood pressure in guinea-pigs with senktide- induced hypertension)
NK3 agonists increase the blood pressure in guinea pigs. The senktide- induced hypertension can be antagonized by administering compounds with NK3- antagonistic properties. Measuring the level of hypertension is indicative for the degree of activity of the test compounds. The own effect of the tested compound is assessed in the same experiment to exclude an additional hypertensional effect.
Male Dunkin Hartley guinea pigs with a body weight between 450 and 550 g were anesthetized with Ketamin (200 mg/kg i.m.; Aescoket 10%) and the left carotid artery and left jugular vein were cannulated for blood pressure measurement and drug application, respectively. The animals were allowed to breathe spontaneously.
Blood pressure was measured with a strain gauge transducer connected to a computer via an amplifier.
After hemodynamic stabilization two subsequent injections of the NK3-receptor agonist senktide (0.4 μg/kg i.v.; 0.5 ml/kg) were given with an interval of 15 minutes and the peak increase in mean arterial blood pressure of each injection determined. The mean value of the increase in blood pressure served as the pre-drug hypertensive effect of senktide. Five minutes thereafter the test compound was given as an infusion over 10 min (0.1 ml/min), immediately followed by an injection of 0.4 μg/kg senktide and the peak increase in mean arterial blood pressure determined. Up to 5 cycles of additive test compound dosages were applied and the hypertensive effect of senktide determined after each dose. The effect of the test compound on the peak rise in blood pressure induced by senktide is expressed as percentage relative to the pre-drug value. ID50 values (dose that produces a 50% inhibition of the senktide response) were calculated from the dose response curve. The effect of the vehicle on the senktide induced pressure response was determined on regular base.
For oral administration, vehicle (1 % methylcellulose) or test compound was administered in a dose volume of 5 ml/kg. Forty five minutes thereafter, anesthesia was induced and the carotid artery and jugular vein were cannulated. After a 10 minutes period for hemodynamic stabilization, two subsequent injections of the NK3- receptor agonist senktide (0.4 μg/kg i.v.; 0.5 ml/kg) were given with an interval of 15 minutes and the peak increase in mean arterial blood pressure of each injection determined. The first senktide injection was approximately 80 to 90 minutes post dosing. The mean value of the increase in blood pressure served as the hypertensive effect of senktide in that animal. The mean hypertensive effect of senktide following vehicle treatment served as the control value (100%). The effect of each test compound dose on the peak rise in blood pressure induced by senktide is expressed as percentage relative to this control value and averaged per dose group. ID50 values (dose that produces a 50% inhibition of the senktide response) were calculated from the dose response curve.
Senktide (0.8 μg/ml) was dissolved in saline. For intravenous administration, the test compounds were dissolved in 40% hydroxypropyl-β-cyclodextrine (HPCD) containing 10% DMSO, diluted with saline and administered intravenously in cumulative dose ranges. A vehicle group of animals received the corresponding HPCD/DMSO solutions instead of the test compound. For oral administration, the test compound was suspended in 1 % methylcellulose. A vehicle group of animals received the corresponding HPCD/DMSO solutions instead of the test compound.
Table 12: Inhibition of blood pressure as ID50-value after intravenous (iv) and oral (po) administration
Figure imgf000041_0001
10. Determination of the NK1 - and NK2-receptor-antagonistic effectiveness of the test substances in vivo
The NK1- and NK2-antagonistic activities of the test substances were investigated in anaesthetised guinea pigs in each case after intravenous (= i.v.) and oral (= p.o.) administration in vivo. With the present test model it is possible to detect both NK2-antagonistic effects in three different organ systems (respiratory tracts, colon and circulation) and NK1 -antagonistic effects (rapid drop in blood pressure) in an animal simultaneously.
Pirbright-White guinea pigs of a body weight of 500-700 g were anaesthetised with ketamine/xylazine (67/13 mg/kg subcutaneously, initial dose, further doses administered as required). The animals were provided with an intravenous catheter in order to administer the substance and an intra-arterial catheter to measure the blood pressure. The animals were artificially ventilated via a tracheal cannula and the respiratory pressure was recorded by means of a pressure transducer. A balloon was introduced into the distal colon of the animals for manometric recording of colon motility by means of a pressure transducer. Blood pressure, heart rate, respiratory pressure and colonic pressure were measured continuously for each animal and plotted on a recorder and by means of a digital data-processing system. Neurokinin A (= NKA; 200 pmol/animal) was administered i.v. as a bolus as a test stimulus to stimulate the NK1- and the NK2-receptors. NKA injection resulted in an increase in respiratory pressure (bronchoconstriction) and colonic pressure, and in a biphasic drop in blood pressure. The first phase of hypotension (= phase of maximum hypotension within the first minute after administration of NKA) is mediated via NK-1 receptors, since they can be blocked completely by specific NK-1 receptor antagonists. The second phase of delayed hypotension (= phase of maximum hypotension after 2-5 min.) on the other hand is mediated via NK2-receptors, since they can be blocked by specific NK2- receptor antagonists. The doses of the test substances are given as ED50 values which each result in a response to the NKA test stimulus which is reduced to 50% of the initial value, as characteristic variables for the individual measurement parameters bronchoconstriction, colonic pressure and change in blood pressure mediated by NK1 or NK2. The antagonistic effects of the test substances were first investigated in cumulative form, the time of the NKA test stimulus being 1 min after the administration of the respective doses of the test substances had ended. These ED50 values obtained from cumulative dose effect curves are plotted in table 13.
Table 13: NK1- and NK2-receptor-antagonistic potency of the test substances of Formula I on guinea pigs in vivo after intravenous administration
Figure imgf000043_0001
The measured values plotted in table 14 above show, inter alia, that the compounds of Example No. 1 1 after cumulative administration i.v. (detection of the antagonism 1 min. after the administration of test substance had ended) caused a marked NK-1 -receptor-antagonistic activity on the early hypotension. The data show further that compounds of all Example No. caused a marked NK2-receptor-antagonistic activity of colon motility, late drop in blood pressure and respiratory resistance.
In order additionally to detect the variation over time of the antagonistic effects of the test substances, the action of the NKA test stimulus was determined at different times (1 , 30, 60, 90, 120, 150 and 180 min.) after oral administration of the test substances. The antagonistic effects of the test substances were then determined as "area under the curve" ("AUC") over the investigation period after administration of the test substances (1 - 180 min after administration) and the ED50 values after oral administration obtained therefrom were plotted in table 14.
Table 14: NK1- and NK-2-receptor-antagonistic potency of the test substances of Formula I on guinea pigs in vivo after oral administration
Figure imgf000044_0001
The compounds according to the invention, in particular the compounds of Example No. 1 , 4, 8 and 1 1 as shown in table 15, are furthermore active orally on the NK2. Example 1 1 was also active as NK1 receptor antagonists.
The compounds of Formula I may be administered in conventional pharmaceutical preparations. The doses to be used may vary individually and will naturally vary according to the type of condition to be treated and the substance used. In general, however, medicinal forms with an active substance content of 0.2 to 200 mg, in particular 1 to 50 mg, active substance per individual dose are suitable for administration to humans and larger mammals. The compounds may be contained according to the invention, together with conventional pharmaceutical auxiliaries and/or carriers, in solid or liquid pharmaceutical preparations. Examples of solid preparations are preparations which can be administered orally, such as tablets, coated tablets, capsules, powders or granules, or alternatively suppositories. These preparations may contain conventional pharmaceutical inorganic and/or organic carriers, such as talcum, lactose or starch, in addition to conventional pharmaceutical auxiliaries, for example lubricants or tablet disintegrating agents. Liquid preparations such as suspensions or emulsions of the active substances may contain the usual diluents such as water, oils and/or suspension agents such as polyethylene glycols and the like. Other auxiliaries may additionally be added, such as preservatives, taste correctives and the like.
The active substances may be mixed and formulated with the pharmaceutical auxiliaries and/or carriers in known manner. For the production of solid medicament forms, the active substances may for example be mixed with the auxiliaries and/or carriers in conventional manner and may be wet or dry granulated. The granules or powder can be poured directly into capsules or be pressed into tablet cores in conventional manner. These may be coated in known manner if desired.
The following examples are intended to explain the invention further, without limiting its scope.
The LC-MS data (API) were obtained by the following conditions: Instrument- Description: API 100 Single Quad, PE Applied Biosystems
PE 200 BI LC-Pump, PE Applied Biosystems Gilson XL 215 Autosampler, Gilson Inc.
Sedex 75 Lightscattering-Detector, S.E.D.E.R.E Column: XTerra MS C18, 2.5 urn, 50 x 4.6 mm
Guard-Column: XTerra MS C18, 3.5 urn, 20 x 3.9 mm
Solvent A: 0.01 M NH4ac pH 5.0 + 5 % Acetonitrile Solvent B: Acetonitrile
Gradientprofile: 100 % A — 10min — >95 % B
2min isocratic 95 % B
100 % A <— 0.5min — 95 % B
100 % A 2.5min isocratic Flow: 1.0 ml / min
Wavelength: 225 nm
The LC-MS data (ZQ) were obtained by the following conditions: Instrument- Description: ZQ Single Quad, Waters / Micromass Alliance HT 2795, Waters PL-ELS 1000 Lightscattering-Detector, Polymer Labs
Column: XTerra MS C18, 2.5 urn, 50 x 4.6 mm Guard-Column: XTerra MS C18, 3.5 urn, 10 x 2.1 mm Solvent A: 0.01 M NH4ac pH 5.0 + 5 % Acetonitrile Solvent B: Acetonitrile Gradientprofile: 100 % A 1 min isocratic
100 % A — 6min — > 95 % B
1 min isocratic 95 % B
100 % A <— 1 min — 95 % B
100 % A 2min isocratic
Flow: 1.0 ml / min Wavelength: 205-350 nm
Example 1 : Synthesis of Λ/-[(2S)-2-(3,4-dichloroprienyl)-4-oxobutyl1-Λ/-methyl- benzamide as starting material for the preparation of example compounds 1 , 2 and 99
Figure imgf000046_0001
In a solution of 15 ml (0.172 mol) of oxalyl chloride in 200 ml of methylene chloride cooled to -60/-700C under nitrogen were added in 75 minutes dropwise in order to maintain the temperature at -60/-700C 30 ml of DMSO in 100 ml methylene chloride. The reaction mixture was stirred for 20 minutes at -70°C and subsequently a suspension of 31 g (0.088 mol) of N-[2-(3,4-Dichloro-phenyl)-4-hydroxy-butyl]-N- methyl-benzamide in 200 ml of methylene chloride were added in 60 minutes in a way to maintain the temperature of the reaction mixture at -600C. As this temperature were added dropwise 90 ml of triethylamine in 40 ml methylene chloride. The mixture was let to come back to room temperature slowly and allowed to stay for 15 hours. The reaction mixture was concentrated in vacuum and the residue was dissolved in a mixture of 200 ml toluene and 200 ml ethyl acetate. The organic phase was washed by 100 ml of a saturated solution of NaCI in water and 4 times with 100 ml water each. The recovered organic phase was dried on sodium sulphate and concentrated in vacuum to deliver 32.6 g of a glassy material.
17.15 g of the compound were put in suspension in 10 ml methylene chloride under stirring at room temperature. To the suspension were added 50 ml of n-hexane and the mixture was put at 45°C giving a slurry. To the slurry were added 40 ml of n- hexane and the mixture was let to cool down to room temperature. The obtained suspension was filtered off to give a solid which was washed three times with 10 ml n- hexane. After dissolution in methylene chloride and subsequent concentration to dryness 15 g of a solid (melting point: 78-79°C) were obtained: Overall yield: 90%
Example 2: Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-4'-carboxamide (example compound 1 )
Figure imgf000047_0001
To a suspension of 15 g (0.0428 mol) of the aldehyde from example 1 , 14.9 g (0.0540 mol) of [1 ,4']Bipiperidinyl-4'-carboxylic acid dimethylamide hydrochloride and 5.3 g sodium acetate in 800 ml of THF at room temperature under stirring were added 5 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 18.5 g (0.0876 mol) of sodium triacetoxy-borohydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 300 ml ethyl acetate, 50 ml of MTBE and 6 g of KOH dissolved in 100 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 100 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness to give 27 g of the raw base as a foam. 17 g of raw base were dissolved in 30 ml of methylene chloride at room temperature to which 13 ml of 5N HCI in isopropanol were added and a solution was obtained. To the solution were added 500 ml of MTBE and a solid appeared. The suspension was heated to 500C and cooled down. The solid was recovered by filtration, washed 3 times with 100 ml of MTBE. The solid was dissolved in 100 ml methanol and concentrated to dryness to give 16.2 g of the compound identified as dihydrochloride in elemental analyses. Yield: 90%. Optical rotation: -16.3° (c=1 % in methanol).
Raw base purified by dissolution in water in the presence of concentrated HCI gives after elimination of insoluble by- products by extraction with MTBE and basification by means of KOH of the water phase and subsequent extraction of the base using methylene chloride a pure base as a yellowish compound with a 90%-yield. Optical rotation; -17.8° (c= 1 % in methanol).
1HNMR(as base) (500 MHz, CDCI3 , 300C) δ: 7.40-7.25 (m, 4.6H), 7.25-7.0 (m, 2.7H), 6.9, 6.7 (2xbs, 0.7H), 3.82 (bs, 0.7H), 3.55 (dd, 0.7H), 3.5-3.25 (m, 4.4 H), 3.2 (bs, 0.7 H), 3.0 (m, 2H), 2.95-2.90 (2xs, 3H), 2.8-2.5 (m, 4.5H), 2.4-1.6 (m, 12H), 1.5 (s, 4H), 1 ,4 (s, 2H).
13CNMR (125MHz, CDCI3 , 300C) δ: 173.5, 171.6, 143.0, 136.4., 132.4, 130.5, 128.4, 126.8, 66.9, 57.1 , 56.1 , 53.3, 51.7, 47.3, 41.7, 38.7, 37.7, 33.6, 30.9, 26.9, 25.2. LC-MS: M+1 (monoisotope) 573. Retention time: 7.90 min (API); 5.38 min (ZQ).
Example 3: Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1-Λ/-methyl-1 ,4'-bipiperidine-4'-carboxamide (example compound 2)
Figure imgf000048_0001
To a suspension of 15 g (0.0428 mol) of the aldehyde from example 1 , 14.1 g (0.0540 mol) of [1 ,4']Bipiperidinyl-4'-carboxylic acid methylamide hydrochloride and, 5.3 g sodium acetate in 800 ml of THF at room temperature under stirring were added 5 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 18.5 g (0.0876 mol) of sodium triacetoxyboro-hydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 300 ml ethyl acetate, 50 ml of MTBE and 6 g of KOH dissolved in 100 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 100 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness to give 27 g of the raw base as an foam. 17 g of raw base were dissolved in 30 ml of methylene chloride at room temperature to which 13 ml of 5N HCI in isopropanol were added and a solution was obtained. To the solution were added 500 ml of MTBE and a solid appeared. The suspension was heated to 500C and cooled down. The solid was recovered by filtration, washed 3 times with 100 ml of MTBE. The solid was dissolved in 100 ml methanol and concentrated to dryness to give 16.2 g of the compound identified as dihydrochloride in elemental analyses. Yield: 100%. 1HNMR(as base) (500 MHz, CDCI3 ) δ: 7.45-6.70. (m, 9H), 3.84 (bs, 0.7H), 3.55-2.8 (m, 4.3H), 2.78-2.75 (2xs, 3H), 2.7-2.5 (m, 3H), 2.4-1.6 (m, 14H), 1.5 (s, 4H), 1 ,4 (s, 2H). 13CNMR (125MHz, CDCI3 , 300C) δ: 176.9, 171.6, 143.0, 136.4., 132.4, 130.5, 128.3, 126.7, 64.6, 57.2, 56.0, 53.4, 50.8, 47.3, 41.7, 38.7, 34.2, 30.4 ,29.5, 27.2, 25.8, 24.9 LC-MS: M+1 : 559. Retention time: 6.98 (API)
Example 4: Synthesis of 1-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)- butyl1-Λ/,Λ/-dimethyl-4-pyrrolidin-1-ylpiperidine-4-carboxamide (example compound 99):
Figure imgf000049_0001
Here: synthesis of Λ/,Λ/-dimethyl-4-pyrrolidin-1-ylpiperidine-4-carboxamide as starting material
Figure imgf000050_0001
Ethyl 1-benzyl-4-[(4-chlorobutanoyl)amino1piperidine-4-carboxylate
Figure imgf000050_0002
78.3 g (0.298 mol) ethyl 4-amino-1-benzylpiperidine-4-carboxylate and 50 ml pyridine (0.6 mol, 2 eq) were dissolved in 1 L CH2CI2. The mixture was cooled to 50C and 0.37 ml chlorobutyryl chloride (0.33 mol, 1.1 eq) dissolved in 200 ml CH2CI2 was added drop wise. The mixture was stirred over the weekend at ambient temperature. 800 ml of a saturated solution of NaHCO3 were added and the organic layer was separated. The water layer was extracted with CH2CI2 (2x 500 ml). The organic layer was washed with NaHCO3 (2x 800 ml) and evaporated to dryness. The mixture was purified over Silica (eluent: CH2CI2/Me0H, 100/0 to 97/3 to 95/5, v/v). Yield: 1 13 g (~ quantitative yield) of a yellow semi solid.
Ethyl 1-benzyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxylate
Figure imgf000050_0003
12 g sodium hydride (290 mmol, 1.2 eq) were suspended in 600 ml THF. To this suspension was added a gel of 88.5 g of ethyl 1-benzyl-4-[(4-chlorobutanoyl)- amino]-piperidine-4-carboxylate (240 mmol, 1 eq) in 200 ml THF. The mixture was stirred overnight at room temperature. NMR analysis revealed 60-70% conversion. 5 g of extra sodium hydride (120 mmol, 0.5 eq) and 9 g (60 mmol, 0.3 eq.) sodium iodide were added and the mixture was stirred for another day at room temperature. NMR analysis revealed now complete conversion. The reaction was quenched with 1 L of water. The mixture was extracted with ethyl acetate (3x 1 L). The organic layer was washed with 500 ml of a saturated solution of sodium chloride in water. The combined water layers were extracted with dichloromethane (2x 1 L). The combined organic layers were evaporated to dryness. The crude mixture was further purified over Silica (eluent: CH2CI2/Me0H, 100/0 to 95/5, v/v) yielding 68.4 g of the target compound (207 mmol, 67%) as light yellow solid.
1-Benzyl-Λ/,Λ/-dimethyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxamide
Figure imgf000051_0001
65 g (200 mmol, 1 eq) of ethyl 1-benzyl-4-(2-oxopyrrolidin-1-yl)piperidine-4- carboxylate was dissolved in 600 ml THF and 400 ml 1 M NaOH was added. The mixture was stirred at reflux overnight. TLC analysis revealed not complete conversion. 100 ml 1 M extra NaOH was added and the mixture was stirred at reflux for another 2.5 h. The mixture was cooled to ambient temperature and diluted with 500 ml of water. The mixture was extracted with CH2CI2 (2x 500 ml). The water layer was cooled and neutralized with concentrated HCI (ca. 20 ml). The mixture was concentrated in vacuum to dryness.
This crude mixture was suspended in 1 L dichloromethane). Dimethylamine HCI salt (21.9 g, 270 mmol, 1.35 eq), TBTU (86.7g, 270 mmol, 1.35 eq) and triethyl amine (138 ml, 1.0 mol, 5 eq) were added. The mixture was stirred overnight at room temperature. The mixture was diluted with CH2CI2 (500 ml) and washed with water (500 ml), NaHCO3 (500 mL), water and a saturated solution of sodium chloride in water (250 ml). The mixture was evaporated to dryness. The crude mixture was purified over Silica (eluent: CH2CI2/Me0H, 95/5, v/v).
Yield: 30.8 g of 1-Benzyl-N,N-dimethyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxamide (93.5 mmol, 52%) as light yellow solid.
Λ/,Λ/-Dimethyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxamide
Figure imgf000052_0001
Benzyl-N,N-dimethyl-4-(2-oxopyrrolidin-1-yl)piperidine-4-carboxamide (29 g, 88 mmol) was dissolved in fert.-Butanol / water (600 ml, 9/1 , v/v). Pd-C (6 g, 10%, wet) was added and the mixture was stirred in hydrogen atmosphere (5 bar) at 5O0C for 16 h. NMR analysis revealed complete conversion. The Pd-C was removed by filtration over celite. The celite crop was washed with fert.-Butanol / water (100 ml_, 9/1 , v/v). The volatiles were removed by evaporation in vacuum. The mixture was further purified over Silica (eluent: CH2CI2/ 3 N ammonia in methanol, 95/5 to 90/10, v/v). The appropriate fractions were pooled and concentrated to dryness. Yield: 18 g (75 mmol, 86%) as white solid.
Λ/,Λ/-Dimethyl-4-pyrrolidin-1-ylpiperidine-4-carboxamide
Figure imgf000052_0002
To the suspension of 1 g (4.2 mmol) N,N-dimethyl-4-(2-oxopyrrolidin-1-yl)- piperidine-4-carboxamide in the 50 ml absolute tetrahydrofuran 1.8 ml Redal (sodium- bis-(2-methoxyethoxy)-dihydroaluminate) (3.5M/toluene, 6.3 mmol) was drop wise added. The resulting solution was vigorously stirred for 4h at the room temperature, then reaction was quenched by the addition of 20 g NaF followed by 5 ml of 80% aqueous tetrahydrofuran solution. The resulting slurry was stirred for another hour, then solids were filtered off, gently washed with 2x50 ml tetrahydrofuran and organic phase was evaporated under reduced pressure. Crude amine was further purified by column chromatography over silica gel (acetonitrile 6.25 : aqueous ammonia 25% 1 ) delivering pale yellow oil with slowly crystallizes on standing (330 mg, 35%). Melting point: 1500C.
Synthesis of 1-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)-butyl1-Λ/,Λ/- dimethyl-4-pyrrolidin-1-ylpiperidine-4-carboxamide (example compound 99)
Figure imgf000053_0001
To a suspension of 150 mg (0.0428 mmol) of the aldehyde from example 1 , 96 mg (0.0428 mmol) of N.N-dimethyW-pyrrolidin-i-ylpiperidine^-carboxamide and 0,5 g sodium acetate in 21 ml of THF at room temperature under stirring were added 0.05 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 0.13 g (0.062 mmol) of sodium triacetoxyborohydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 6 ml ethyl acetate, 10 ml of MTBE and 0.12 g of KOH dissolved in 5 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 10 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness. Crude amine was further purified by column chromatography over silica gel (ethyl acetate 10: triethylamine 1 ; Rf=0.35) delivering 109 mg of a colourless amorphous foam (45%).
1HNMR (500 MHz, CDCI3) δ: 7.45-7.25 (m, 4.5H), 7.25-7.0 (m, 3H), 6.9, 6.75 (2xbs, 0.6H), 3.85 (bm, 0.6H), 3.51 (bdd, J=12.5, 10.1 Hz, 1 H), 3.5-2.75 (m, 9H), 2.7 (bs, 2H), 2.6 (bs, 4H), 2.4-1.7 (m, 9H), 1.65 (bs, 4H). ). 13CNMR (125MHz, CDCI3) δ: 173.3, 171.5, 142.9, 136.4, 130.5, 130.2, 129.5, 128.4, 127.3, 126.8, 63.2, 56.1 , 55.8, 53.3, 51.8, 51.3, 45.0, 42.5, 41.7, 38.8, 37.9, 30.6, 28.0, 24.1.
LC-MS: M+1 : 559. Retention time: 5.44 min (API).
Example 5: Synthesis of (2fi)-1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichloro- phenyl)butyl1-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-2-carboxamide (example compound 100 in RS-confiquration)
Figure imgf000054_0001
1 g of (7.75 mmol) L-pipecolic acid and 1.6 g (8.0 mmol) N-Boc-piperidin-4-one were dissolved in 20 ml dichloromethane. To this solution 0.48 ml acetic acid was added and after 30 min., 3.27 g (2 eq) of sodium triacetoxyborohydride were added. The resulting suspension was stirred for 24 h at room temperature. The reaction mixture was diluted with 30 ml of a saturated solution of sodium chloride in water and the product was extracted with 6 x 20 ml dichloromethane. The organic phase was dried over Na2SCU and evaporated under reduced pressure to yield 2.4 g of [1 ,4']- bipiperidinyl-2, 1 '-dicarboxylic acid 1 '-tert-butyl ester.
2.4 g (7.7 mmol) of [1 ,4']-bipiperidinyl-2,1 '-dicarboxylic acid 1 '-tert-butyl ester were dissolved in 20 ml dichloromethane and 8 ml (2M/THF, 16 mmol) dimethylamine, 1.75 ml (16 mmol) N-methyl-morpholine, 2.1 g (16 mmol) N- hydroxymethylbenzotriazole were added. Finally 3 g (16 mmol) of EDC *HCI (ethyl-n1- (3-dimethylaminopropyl)-carbodiimide HCI salt) were added and reaction mixture was stirred for 2Oh at room temperature. The reaction mixture was diluted with 50 ml ethyl acetate and washed with 2 x 20 ml 10% K2CO3/water solution. The organic phase was separated, dried over anhydrous sodium sulphate and evaporated under reduced pressure. The crude amide was purified by column chromatography over silica gel (ethyl acetate 2: ethanol 1 , Rf=0.45) yielding 1.4 g colorless solid 2-dimethylcarbamoyl- [1 ,4']-bipiperidinyl-1 '-carboxylic acid tert-butyl ester (53%). [Q]22 D= +47° , c=1 , MeOH.
1.4 g (4.13 mmol) 2-dimethylcarbamoyl-[1 ,4']-bipiperidinyl-1 '-carboxylic acid tert-butyl ester were dissolved in 1 ml dichloromethane and then 10 ml 6M HCI/isopropanol were added. The reaction mixture was stirred at room temperature for 3 h in which time, product crystallized in the reaction medium. The suspension was diluted with 50 ml MTBE, allowed to stir 30 more minutes, then filtered and washed with MTBE. The solid was dried under high vacuum for 1 h to remove traces of volatile materials yielding 1.17 g white powder [1 ,4']-bipiperidinyl-2-carboxylic acid dimethylamide (91 %).
To a suspension of 150 mg of the aldehyde from example 1 (0.0428 mmol), 135 mg (0.0428 mmol) of [1 ,4']-bipiperidinyl-2-carboxylic acid dimethylamide and 0,5 g sodium acetate in 21 ml of THF at room temperature under stirring were added 0.05 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 0.13 g (0.062 mmol) of sodium triacetoxyborohydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 6 ml ethyl acetate, 10 ml of MTBE and 0.12 g of KOH dissolved in 5 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 10 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness. Crude amine was further purified by column chromatography over silica gel (ethyl acetate 10: methanol 1 : triethyl amine 1 ; Rf=0.35) delivering 121 mg of a colourless amorphous foam (49%).
[Q]22D= -46.5° : C=I 1 CHCI3. 1HNMR (500 MHz, CDCI3) δ: 7.45-7.3 (m, 4.5H), 7.25-7.0 (m, 2.8H), 6.9, 6.75 (2xbs,
0.65H), 3.85 (bm, 0.65H), 3.6-3.4 (m, 1 H), 3.55 (dd, J=13.1 , 9.5 Hz, 1 H), 3.25 (bs, 3H),
3.0 (m, 2H), 2.9 (s, 3H), 2.75 (m, 2H), 2.6 (bs, 2H), 2.4 (m, 1 H), 2.2 (dt, J=1 1.0, 2.4 Hz,
1 H), 2.18 (m, 1 H), 2.0-1.3 (m, 14H), 1.25 (m, 1 H).
13CNMR (125MHz, CDCI3) δ: 173.1 , 171.6, 142.9, 136.4, 132.7, 132.5, 130.5, 130.2, 129.5, 128.4, 127.2, 126.7, 63.9, 58.7, 55.9, 53.8, 53.6, 53.4, 45.5, 42.3, 41.4, 38.8,
36.8, 36.2, 34.5, 33.5, 30.8, 30.3, 28.9, 25.8, 24.3, 23.9.
LC-MS: M+1 =573.
Retention time: 4.73 min (API).
Example 6: Synthesis of (2S)-1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichloro- phenyl)-butyl1-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-2-carboxamide (example compound 100 in SS-configuration)
Figure imgf000056_0001
See procedure for example 5. Instead of L-pipecolic acid, D-pipecolic acid is used yielding to 1.267 g of white crystalline amine salt (2S)-1 '-[(3S)-4- [benzoyl(methyl)amino]-3-(3,4-dichloro-phenyl)butyl]-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-2- carboxamide and after the consequent steps including purification (ethyl acetate 10: methanol 1 : triethyl amine 1 ; Rf=0.35) to 69 mg colorless amorphous foam (28%).
[α]22 D= -16.2° , c=1 , CHCI3.
1HNMR (500 MHz, CDCI3) δ: 7.45-7.3 (m, 4.5H), 7.25-7.0 (m, 2.8H), 6.9, 6.75 (2xbs, 0.65H), 3.85 (bm, 0.65H), 3.6-3.4 (m, 1 H), 3.55 (m, 1 H), 3.23 (bs, 3H), 3.0 (m, 2H),
2.95 (s, 3H), 2.68 (m, 2H), 2.4 (m, 1 H), 2.2 (dt, J=11.0, 2.4 Hz, 1 H), 2.18 (m, 1 H), 2.0-
1.3 (m, 14H), 1.25 (m, 1 H).
13CNMR (125MHz, CDCI3) δ: 173.1 , 171.7, 142.8, 136.0, 132.5, 130.6, 130.2, 129.5,
128.4, 127.2, 126.7, 63.8, 58.7, 56.0, 54.1 , 53.4, 53.2, 45.5, 42.5, 41.5, 38.9, 36.8, 36.2, 34.5, 33.7, 30.7, 30.2, 28.9, 25.7, 24.2, 23.8.
LC-MS: M+1 = 573.
Retention time: 4.73 min (API).
Example 7: Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichloro-phenyl)- butyl1-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-2-carboxamide (example compound 100)
Figure imgf000056_0002
See procedure for example 5. Instead of L-pipecolic acid or D-pipecolic acid, (D-L)-pipecolic acid is used yielding to 1.267 g of white crystalline amine salt (2)-V- [(3S)-4-[benzoyl(methyl)amino]-3-(3,4-dichloro-phenyl)butyl]-Λ/,Λ/-dimethyl-1 ,4'-bi- piperidine-2-carboxamide and after the consequent steps including purification (ethyl acetate 10: methanol 1 : triethyl amine 1 ; Rf=0.35) to 69 mg colorless amorphous foam (28%).
[α]22 D= -16.2° , c=1 , CHCI3.
1HNMR (500 MHz, CDCI3) δ: 7.45-7.3 (m, 4.5H), 7.25-7.0 (m, 2.8H), 6.9, 6.75 (2xbs, 0.65H), 3.85 (bm, 0.65H), 3.6-3.4 (m, 1 H), 3.55 (m, 1 H), 3.23 (bs, 3H), 3.0 (m, 2H), 2.95 (s, 3H), 2.68 (m, 2H), 2.4 (m, 1 H), 2.2 (dt, J=11.0, 2.4 Hz, 1 H), 2.18 (m, 1 H), 2.0- 1.3 (m, 14H), 1.25 (m, 1 H).
13CNMR (125MHz, CDCI3) δ: 173.1 , 171.7, 142.8, 136.0, 132.5, 130.6, 130.2, 129.5, 128.4, 127.2, 126.7, 63.8, 58.7, 56.0, 54.1 , 53.4, 53.2, 45.5, 42.5, 41.5, 38.9, 36.8, 36.2, 34.5, 33.7, 30.7, 30.2, 28.9, 25.7, 24.2, 23.8. LC-MS: M+1 =573.
Retention time: 4.73 min (API).
Example 8: Synthesis of Λ/-[(2S)-2-(3,4-dichlorophenyl)-4-(4-{1-[(dimethylamino)- carbonyl1cvclohexyl)piperazin-1-yl)butyl1-Λ/-methylbenzamide (example compound 96):
Figure imgf000057_0001
Here: synthesis of 1-(4-benzylpiperazin-1-yl)-Λ/,Λ/-dimethylcyclo-hexanecarboxamide as starting material
Figure imgf000057_0002
7.9 g (0,0262 mol) of 1-(4-benzylpiperazin-1-yl)-cyclohexanecarboxamide (known from WO0058292) in 120 ml of anhydrous THF was added drop wise at room temperature under stirring to a suspension of 2.83 g (0.071 mol) of sodium hydride 60% in oil in 120 ml of anhydrous THF under nitrogen. The mixture was then heated to 600C for 2 hours under stirring. After cooling down of the reaction mixture to room temperature, a solution of 6.33 g of methyl iodide in 80 ml of anhydrous DMF was added at room temperature and the reaction mixture was further stirred for 5 days. The reaction mixture was then poured on 500 g of iced water and the product extracted with 500 ml MTBE. The organic layer was recovered and washed with 500 ml of a saturated solution on sodium chloride in water. The organic phase was then dried on sodium sulphate and concentrated to dryness. The HPLC-MS shows the presence of the expected compound as well as of its monomethylated analogue.
The mixture was then separated by column chromatography on silicagel with n- hexane: 1/ ethyl acetate 9 to deliver 3.2 g of the expected compound (yield: 38%).
Here: synthesis of A/./V-dimethyl-i-piperazin-i-ylcyclohexane-carboxamide as starting material
Figure imgf000058_0001
3.2 g (0.0097 mol) of the 1-(4-benzylpiperazin-1-yl)-Λ/,Λ/-dimethylcyclo- hexanecarboxamide was dissolved in 100 ml ethanol and 0.7 ml of acetyl chloride were added. Subsequently 1 g of 10% palladium on charcoal was added and the suspension was hydrogenated at 3 bars at room temperature for 15 hours. The catalyst was separated by filtration and washed with 25 ml ethanol. The solvent was then distilled off to deliver 2.6 g of Λ/,Λ/-dimethyl-1-piperazin-1-ylcyclohexane- carboxamide as a crystalline hydrochloride (yield: 97%). Melting point: 230-10C.
Synthesis of Λ/-[(2S)-2-(3,4-dichlorophenyl)-4-(4-{1-[(dimethylamino)- carbonyl1cvclohexyl)piperazin-1-yl)butyl1-Λ/-methylbenzamide (example compound 96):
Figure imgf000059_0001
To a suspension of 150 mg of the aldehyde from example 1 (0.0428 mmol), 130 mg (0.0428 mmol) of /V./V-dimethyl-i-piperazin-i-ylcyclohexane-carboxamide hydrochloride and 0,5 g sodium acetate in 21 ml of THF at room temperature under stirring were added 0.05 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 0.13 g (0.062 mmol) of sodium triacetoxyborohydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 6 ml ethyl acetate, 10 ml of MTBE and 0.12 g of KOH dissolved in 5 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 10 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness. Crude amine was further purified by column chromatography over silica gel (ethyl acetate 10: methanol 1 : triethyl amine 1 ; Rf=0.35) delivering 260 mg of a colourless amorphous foam (85%) as dihydrochloride.
1HNMR(as hydrochloride) (500 MHz, CD3 OD) δ: 7.65-6.95 (m, 8H), 3.82 (m, 2H), 3.80-3.5 (m, 3H), 3.2-2.9 (m, 15H), 2.8 (m, 2H), 2.5-1.1 (m, 12H).
13CNMR (125MHz, CD3 OD ) δ: 174.1 , 142.7, 137.3., 133.8, 132,5, 132.1 , 129.7, 129.1 , 128.1 , 127.7, 58.2, 56.0, 53.7, 51.7, 47.3, 42.1 , 39.2, 28.5, 27.1 , 25.1 LC-MS: M+1 (monoisotope): 585. Retention time: 5.22 min (API).
Example 9: Synthesis of H(3S)-4-[benzoyl(methyl)amino1-3-(3,4-dichlorophenyl)butyl1- 4-cyclohexyl-Λ/,Λ/-dimethyl-piperidine-4-carboxamide (example compound 95)
Figure imgf000060_0001
5 g (13.25 mmol) 4-phenyl-4-pipeιϊdinecarboxylic acid tosylate salt was dissolved in 50 ml of dichloromethane, then 3.75 ml (27 mmol) triethylamine and 3.1 g (14 mmol,) bis- fert-butyloxycarbonate were added. The reaction mixture was stirred for
16 h, then diluted with 100 ml of ethyl acetate and washed with 1x 50 ml 10% aqueous acetic acid and with 3x 50 ml of a saturated solution of sodium chloride in water. The organic phase was separated, dried over anhydrous sodium sulphate and evaporated under reduced pressure yielding 3.97 g white crystals of N-Boc-4-phenyl-4- piperidinecarboxylic acid (98%).
13 mmol N-Boc^-phenyW-piperidinecarboxylic acid was dissolved in 100 ml ethanol and hydrogenated with hydrogen (6 bars) over 5%-Rh/AI2θ3 at 60° C for 20 h. After filtration and evaporation of solvent, pure crystalline N-Boc-4-cyclohexyl-4- piperidinecarboxylic acid was isolated 4.0 g (100%). Melting point: 156°C.
1 g (3.2 mmol) of N-Boc-4-cyclohexyl-4-piperidine-carboxylic acid was dissolved in 20 ml of dichloromethane and one drop of dimethylformamide was added. To the resulted solution 0.29 ml (1.05 eq) oxalyl chloride was added and solution stirred for 30 min. 3.2 ml of dimethylamine (2M/THF, 2 eq) was added and mixture was stirred for 30 more minutes. Solution was diluted with 50 ml ethyl acetate and washed with 2x 20 ml aqueous 10% potassium carbonate. The organic phase was dried over anhydrous sodium sulphate and evaporated under reduced pressure. Crude amide was purified by column chromatography over silica gel (dichloromethane 20: acetone 1 , Rf=0.3) yielding to 217 mg of N-Boc-4-cyclohexyl-4-piperidine-carboxylic acid dimethylamide as a colorless oil (20%). 217 mg (0.64 mmol) N-Boc-4-cyclohexyl-4-piperidine-carboxylic acid dimethyl- amide was dissolved in 0.5 ml of dichloromethane and then 2 ml 6M HCI/isopropanol were added. The reaction mixture was stirred at room temperature for 3 h in which time product crystallized in the reaction medium. The suspension was diluted with 20 ml MTBE, allowed to stir 30 more minutes and then filtered and washed with MTBE. The solid was dried under high vacuum for 1 h to remove traces of volatile materials yielding 157 mg 4-cyclohexyl-4-piperidinecarboxylic acid dimethylamide hydrochloride (90%) as a white powder.
To a suspension of 95 mg (0.027 mmol) of the aldehyde from example 1 , 75 mg
(0.0428 mmol) of 4-cyclohexyl-4-piperidinecarboxylic acid dimethylamide hydrochloride and 0,3 g sodium acetate in 20 ml of THF at room temperature under stirring were added 0.03 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 0.1 g (0.045 mmol) of sodium triacetoxyborohydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 6 ml ethyl acetate, 10 ml of MTBE and 0.12 g of KOH dissolved in 5 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 10 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness. Crude amine was further purified by column chromatography over silica gel (ethyl acetate 10: triethylamine 1 ; Rf=0.35) delivering 102 mg of a colourless amorphous foam (66%).
1HNMR (500 MHz, CDCI3) δ: 7.45-7.3 (m, 4.5H), 7.25-7.0 (m, 2.7H), 6.9, 6.75 (2xbs, 0.65H), 3.8 (m, 0.5H), 3.6-3.4 (m, 1.5H), 3.15 (m, 0.6H), 3.0 (s, 6H), 2.9-2.5 (m, 4H),
2.2 (m, 0.6H), 2.1 (bd, J=12.5 Hz, 2H), 2.05-1.8 (m, 4H), 1.78 (bd, J=1 1.6 Hz, 2H), 1.6,
(m, 6H), 1.3-1.0 (m, 5H).
13CNMR (125MHz, CDCI3) δ: 173.6, 170.5, 143.0, 135.4, 131.4, 129.6, 129.5, 129.2,
128.4, 127.3, 126.5, 126.2, 125.7, 55.4, 52.3, 51.1 , 50.6, 49.5, 42.7, 41.5, 40.6, 37.7, 32.5, 29.7, 27.1 , 26.2, 25.5.
LC-MS: M+1 : 572.
Retention time: 5.57 min (API). Example 1 1 : Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4-pyrrolidin-1-yl-4- (pyrrolidin-1-ylcarbonyl)piperidin-1-yl1butyl)-Λ/-methylbenzamide (example compound 103)
Figure imgf000062_0001
Here: synthesis of 1-benzyl-4-pyrrolidin-1-yl-4-(pyrrolidin-1-ylcarbonyl)piperidine as starting material
Figure imgf000062_0002
2.34 ml (0.0132 mol) of N-benzylpiperidin-4-one, 4.4 ml (0.0527 mol) of pyrrolidine, 1.6 ml (0.02 mol) of chloroform and 38 mg of n-benzyl triethylammonium chloride were stirred at 5°C. To the stirred mixture and by maintaining the temperature at 5°C, was added drop wise a solution of 2.6 g of sodium hydroxide in 5 ml of water. After 15 hours of stirring at 5 0C, 50 ml of water were added and the organic material was extracted 3 times with 10 ml of methylene chloride. The organic phase was separated and washed twice with 30 ml of water. The organic phase was then separated, dried on sodium sulphate and concentrated to dryness delivering 3.426 g of an oily material showing the presence in NMR and MS of the expected compound.
Purification: 3 g of the mixture were separated in MPLC on 1 12 g of SiO2 with n-hexane-etyl ester 1 :1 as eluant mixture delivering 1.94 g of the expected compound as white solid, (according to Lai, J. Org. Chem 1980, p. 3671 ).
Here: synthesis of 4-pyrrolidin-1-yl-4-(pyrrolidin-1-ylcarbonyl)-piperidine as starting material
Figure imgf000063_0001
1.9 g (0.00556 mol) of 1-benzyl-4-pyrrolidin-1-yl-4-(pyrrolidin-1-ylcarbonyl)- piperidine was dissolved in 200 ml of ethanol at 300C and hydrogenated in the presence of 4 spatules of palladium hydroxide 20% on charcoal (moisture 60% ) at 4 bars for 6 hours at 400C. The catalyst was recovered by filtration and the solution concentrated to dryness delivering the expected de-benzylated compound which was identified in NMR and MS and used without further purification.
Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4-pyrrolidin-1 -yl-4-(pyrrolidin-1-ylcarbo- nyl)piperidin-1-yl1butyl)-Λ/-methylbenzamide (example compound 103);
Figure imgf000063_0002
To a suspension of 180 mg (0.51 mmol) of the aldehyde from example 1 , 180 mg (0.51 mmol) of 4-pyrrolidin-1 -yl-4-(pyrrolidin-1-ylcarbonyl)-piperidine and 0,3 g sodium acetate in 20 ml of THF at room temperature under stirring were added 0.03 ml of acetic acid and the mixture was stirred for 5 hours at room temperature. To the mixture were added portion wise 0.2 g (0.09 mmol) of sodium triacetoxyboro-hydride and the mixture was further stirred at room temperature for 15 hours. The mixture was concentrated to dryness in vacuum and re-dissolved in 6 ml ethyl acetate, 10 ml of MTBE and 0.2 g of KOH dissolved in 5 ml of water. The organic phase was washed with sodium hydrogenocarbonate until pH 5-6 and 3 times with 10 ml of water. The organic solution was dried on sodium sulphate and concentrated to dryness. Crude amine was further purified by column chromatography over silica gel (ethyl acetate 10: triethylamine 1 ; Rf=0.35) delivering 236 mg of a colourless amorphous foam (79%). 1HNMR(as base) (500 MHz, CDCI3) δ: 7.45-6.70 (m, 8H), 3.85 (m, 2H), 3.6-3.4 (m,
4H), 3.3-2.5 (m, 10H), 2.35-1.9 (m, 8H), 1.78 (s, 4H), 1 ,67 (s, 4H).
13CNMR (125MHz, CDCI3 ) δ: 172.4, 171.6, 143.0, 136.5, 132,4, 130.5, 129.4, 128.3,
127.3, 126.7, 62.9, 56.1 , 53.3, 51.7, 51.1 , 47.5, 45.1 , 41.7, 38.7, 27.9, 27.4, 24.0, 23.2
LC-MS: M+1 (monoisotope): 585.
Retention time: 5.85 min (API).
Example 12: Synthesis of 3-cvano-Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4-pyrrolidin-1 -yl-
4-(pyrrolidin-1-ylcarbonyl)piperidin-1-yl1butyl)-N-methyl-1-naphthamide (example compound 102)
Figure imgf000064_0001
Here: synthesis of 3-Cvano-naphthalene-1-carboxylic acid [2S-(3,4-dichloro-phenyl)-4- oxo-butyli-methyl-amide as starting material
Figure imgf000064_0002
12.2 g DMSO in 100 ml dichloromethane are added drop wise to 7.3 g oxalyl chloride in 100 ml dichloromethane unter nitrogen at - 7O 0C unter stirring. The resulting mixture was stirred for another 15 minutes before 2O g of [.?S-(3,4-dichloro- phenyl)-4-hydroxy-butyl]-methyl-carbamic acid tert-butyl ester in 200 ml dichloromethane were added. The mixture was stirred at - 70 0C for one hour before 40.3 ml of triethylamine in 50 ml dichloromethane were added drop wise. The solution was stirred at - 70 0C for 15 minutes and then allowed to warm up to room temperature. The solvent was removed and the residue was dissolved in 300 ml of toluene and 200 ml of ethyl acetate. The resulting solution was washed six times with 200 ml of a saturated solution of NaCI in water, dried over sodium sulfate and concentrated to dryness to deliver 19.7 g of S-Cyano-naphthalene-i-carboxylic acid [2S-(3,4-dichloro- phenyl)-4-oxo-butyl]-methyl-amide.
Synthesis of 3-cvano-N-{(2S)-2-(3,4-dichlorophenyl)-4-[4-pyrrolidin-1-yl-4-(pyrrolidin-1- ylcarbonyl)piperidin-1-yl1butyl)-Λ/-methyl-1-naphthamide (example compound 102);
253.8 mg (0.0006 mol) of S-Cyano-naphthalene-i-carboxylic acid [2S-(3,4- dichloro-phenyl)-4-oxo-butyl]-methyl-amide, 150 mg (0.006 mol) of 4-pyrrolidin-1-yl-4-
(pyrrolidin-i-ylcarbonyl)-piperidine and 72 mg ( 0.0012 mol) of acetic acid were dissolved in 20 ml of methylene chloride and stirred for 30 minutes at room temperature. Subsequently, 163.7 mg of sodium triacetoxyborohydride was added and the mixture stirred at room temperature for 3 hours. The reaction mixture was then diluted with 40ml of ethyl acetate and the resulting phase washed twice with 50 ml a
10% aqueous solution of potassium carbonate and once with 50 ml of a saturated sodium chloride water solution. The organic phase was then separated and concentrated to dryness to deliver 280 mg of the title base as an amorphous solid.
1HNMR (500 MHz, CDCI3 , ) δ: 8.24 (0.35H), 8.19(0.65H), 7.97-6.50) (m, 8H), 4.4 (bs, 0.65H), 3.85 (bs , 2H), 3.7-3.25 (m, 3.35H), 3.2 (s,m, 1 H), 3.0-1.9 (m, 10H), 1.8 (s, 4H), 1.68 (s, 4H).
13CNMR (125MHz, CDCI3 ) δ: 172.4, 172.3, 142.5, 136.5, 134.7, 132.4, 131.0, 130.6, 130.5, 130.1 , 128.3, 127.5, 126.7, 125.2, 123.9, 1 18.4,109.0, 63.0, 57.1 , 56.0, 53.3, 51.7, 51.1 , 47.5, 45.1 , 45.0, 41.7, 38.7, 37.7, 33.6, 31.6, 27.9, 27.4, 24.0 LC-MS: M+1 (monoisotope): 573. Retention time: 7.90 min (API).
Example 13: Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4'-(piperidin-1-ylcarbonyl)- 1 ,4'-bipiperidin-1 '-yl1butyl)-Λ/-methylbenzamide (example compound 104)
Figure imgf000066_0001
Here: synthesis of 1 '-benzyl-4'-(piperidin-1-ylcarbonyl)-1 ,4'-bipiperidine as starting material
Figure imgf000066_0002
1'-benzyl-4'-(piperidin-1-ylcarbonyl)-1 ,4'-bipiperidine was obtained by condensation of 2.34 ml (0.00132 mol) of N-benzylpiperidin-4-one, 5.3 ml (0.00536 mol) of piperidine, 1.6 ml ( 0.002 mol) of chloroform and 38 mg of benzyltriethylammonium chloride. A raw mixture of 4.445 g of an oily material was delivered (yield: 90%), 2 g of which were subsequently purified in preparative HPLC with a gradient acetonitrile/water containing formic acid in 2 runs to deliver 678 mg of the product as diformiate after lyophilisation of the fractions containing the pure expected compound.
Here: synthesis of 4'-(piperidin-1-ylcarbonyl)-1 ,4'-bipiperidine as starting material
Figure imgf000066_0003
576 mg of 1 '-benzyl-4'-(piperidin-1-ylcarbonyl)-1 ,4'-bipiperidine as diformiate was transformed into dihydrochloride, dissolved in 50 ml ethanol and hydrogenated at
400C for 4 days in presence of 50 mg of 10% palladium on charcoal. The catalyst was separated by filtration and washed 3 times with 50 ml ethanol. The organic phases were reunited and concentrated to dryness to deliver 4'-(piperidin-1-ylcarbonyl)-1 ,4'- bipiperidine as a solid dihydrochloride.
Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4'-(piperidin-1-ylcarbonyl)-1 ,4'- bipiperidin-1 '-yl1butyl)-Λ/-metriylbenzamide (example compound 104)
Figure imgf000067_0001
127 mg (0.00036 mol) of the aldehyde from example 1 , 160 mg (0.0036 mol) 4'- (piperidin-1 -ylcarbonyl)-1 ,4'-bipiperidine as a solid dihydrochloride and 35 mg (0.0006 mol) of acetic acid were dissolved in 20 ml of methylene chloride and stirred for 30 minutes at room temperature. Subsequently, 85 mg of sodium triacetoxyborohydride was added and the mixture stirred at room temperature for 3 hours. The reaction mixture was then diluted with 20ml of ethyl acetate and the resulting phase washed twice with 50 ml a 10% aqueous solution of potassium carbonate and once with 50 ml of a saturated sodium chloride water solution. The organic phase was then separated and concentrated to dryness to deliver 206 mg of the title base as a colourless foam in form of the hydrochloride (quantitative yield).
1HNMR(as hydrochloride) (500 MHz, CDCI3 OD) δ: 7.65-6.95 (m, 8H), 3.8 -3.55 (m, 8H), 3.35-3.25 (2xs, 3H), 3.2-2.4 (m, 13H), 2.35-2.15 (m, 2H), 1.95 ( s, 4H ) 1.7 (s, 2H),
1 ,62 (s, 4H).
13CNMR (125MHz, CD3 OD ) δ: 174.1 , 142.7, 137.3., 133.8, 132,5, 132.1 , 129.7,
129.1 , 128.1 , 127.7, 58.2, 56.0, 53.7, 51.7, 47.3, 42.1 , 39.2, 28.5, 27.1 , 25.1
LC-MS: M+1 (monoisotope): 613. Retention time: 6.14 min (API).
Example 13: Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4'-(pyrrolidin-1-ylcarbonyl)- 1 ,4'-bipiperidin-1 '-yl1butyl)-Λ/-methylbenzamide (example compound 124)
Figure imgf000068_0001
Here: synthesis of 1 '-benzyl-1 ,4'-bipiperidine-4'-carbox-amide as starting material
Figure imgf000068_0002
4,5 g (52.8 mmol) of piperidine, 5 g (26.4 mmol) N-benzyl-piperi-din-4-one, 9,5 g (3 eq) of magnesium sulphate and 2.3 ml of N-dimethylacetamide were mixed together and then 2.6 ml (1 eq) of 2-cyano-2-hydroxy-propane were added. The resulting suspension was stirred over 48 h at 55°C whereupon pasty suspension solidifies. Crude product was mixed with 100 ml water and 100 ml ethyl acetate. Organic phase was washed with water (2 x 50 ml), dried over sodium sulphate and evaporated yielding 7 g crude aminonitrile.
1.3 g (3,6 mmol) of the resulted aminonitrile was dissolved in 15 ml 90% wt. sulfuric acid and heated for 10 minutes at 1000C. The resulting solution was poured on ice and then basicified to pH 9 with sodium hydroxide. Crude amine was extracted with ethyl acetate (3 x 30 ml), organic phase washed one time with a saturated solution of sodium chloride in water, dried over sodium sulphate and evaporated. Yield 1 g (92%) light yellow crystals of 1 '-benzyl-1 ,4'-bipiperidine-4'-carboxamide.
Here: synthesis of Λ/,Λ/-diallyl-1 '-benzyl-1 ,4'-bipiperidine-4'-carboxamide as starting material
Figure imgf000069_0001
1 ,75 g (5,83 mmol) of 1 '-benzyl-1 ,4'-bipiperidine-4'-carboxamide was dissolved in 10 ml hexamethylphosphortriamide. To this solution 466 mg (2 eq) sodium hydride
(60% in oil) was added portion-wise and the suspension was stirred at 600C for 2 hours. Then the resulting solution was cooled to room temperature and 1 ml (2 eq) allyl bromide was added over 6 hours via syringe pump. After 24 h reaction was quenched by addition of 10% aqueous ammonium chloride (50 ml) and product extracted with ethyl acetate. The organic phase dried over sodium sulphate and evaporated. Crude compound was purified by column chromatography over silica gel (ethyl acetate 5: ethanol 1 , Rf=O.3) yielding 1 g (45%) of desired Λ/,Λ/-diallyl-1 '-benzyl-
1 ,4'-bipiperidine-4'-carboxamide.
Here: synthesis of 1 '-benzyl-4'-(2,5-dihydro-1 /-/-pyrrol-1-ylcarbonyl)-1 ,4'-bipiperidine as starting material
Figure imgf000069_0002
1 g (2,6 mmol) Λ/,Λ/-diallyl-1 '-benzyl-1 ,4'-bipiperi-dine-4'-carboxamide was dissolved in 50 ml dichloromethane and to the resulted refluxed solution was added portion wise Grubbs-1 catalyst (1 g, 50 mol%) over 36 hours. The solvent was evaporated and product was purified by column chromatography over silica gel (ethyl acetate, Rf= 0.35) yielding 640 mg (70%) of pure 1 '-benzyl-4'-(2,5-dihydro-1 /-/-pyrrol-1- ylcarbonyl)-1 ,4'-bipiperidine.
Here: synthesis of 4'-(pyrrolidin-1-ylcarbonyl)-1 ,4'-bipiperidine as starting material
Figure imgf000070_0001
0.64 g (1 ,81 mmol) of 1 '-benzyl-4'-(2,5-dihydro-1 /-/-pyrrol-1-ylcarbonyl)-1 ,4'- bipiperidine were dissolved in 70 ml ethanol and 200 mg of Pd(OH) 20% over carbon (60% moisture) were added. The compound was hydrogenated with hydrogen under 5 bar pressure. After 4 hours, the catalyst was removed by filtration and solvent evaporated under reduced pressure yielding 470 mg (99%) of blue-gray crystalline powder. Melting point: 144°C.
Synthesis of Λ/-{(2S)-2-(3,4-dichlorophenyl)-4-[4'-(pyrrolidin-1-ylcarbonyl)-1 ,4'-bipiperi- din-1 '-yl1butyl)-Λ/-methylbenzamide (example compound 124)
Figure imgf000070_0002
150 mg (0.005 mol) of the aldehyde from example 1 , 120 mg (0.005 mol) 4'- (pyrrolidin-1 -ylcarbonyl)-1 ,4'-bipiperidine and 35 mg ( 0.0006 mol) of acetic acid were dissolved in 20 ml of methylene chloride and stirred for 30 minutes at room temperature. Subsequently, 85 mg of sodium triacetoxyborohydride was added and the mixture stirred at room temperature for 3 hours. The reaction mixture was then diluted with 20ml of ethyl acetate and the resulting phase washed twice with 50 ml a 10% aqueous solution of potassium carbonate and once with 50 ml of a saturated sodium chloride water solution. The organic phase was then separated and concentrated to dryness to deliver the title compound. After purification, 171 mg of Λ/- {(2S)-2-(3,4-dichlorophenyl)-4-[4'-(pyrrolidin-1 -ylcarbonyl)-1 ,4'-bipiperidin-1 '-yl]butyl}-Λ/- methylbenzamide (66%) were isolated. 1HNMR (500 MHz, CDCI3) δ: 7.45-7.3 (m, 4.6H), 7.25-7.0 (m, 2.8H), 6.9, 6.75 (2xbs,
0.65H), 4.1-3.7 (m, 2H), 3.6-3.4 (m, 3.65H), 3.15 (bs, 0.65H), 3.0 (bs, 1 H), 2.9-2.6 (m,
5H), 2.46 (s, 4H), 2.3-1.85 (m, 8H), 1.75 (bs, 7H), 1.5 (m, 4H), 1.4 (m, 2H).
13CNMR (125MHz, CDCI3) δ: 172.4, 171.6, 142.9, 136.4, 132.4, 130.5, 130.2, 129.4,
128.3, 127.2, 126.7, 66.4, 57.1 , 56.1 , 55.7, 53.3, 51.6, 51.1 , 47.8, 47.2, 42.5, 41.6,
38.7, 33.6, 30.9, 27.4, 27.1 , 26.9, 25.1 , 23.2.
LC-MS: M+1 =598.
Retention time: 5.82 min (API).
Example 14: Alternative synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-(3,4- dichlorophenyl)butyl1-Λ/-ethyl-Λ/-methyl-1 ,4'-bipi-peridine-4'-carboxamide (example compound 95)
Figure imgf000071_0001
100 mg (0.158 mmol) of amide 1 '-[4-(benzoyl-methyl-amino)-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid methylamide were dissolved in 1 ml absolute DMSO and then 21 mg (0.19 mmol) of potassium ferf-butylate were added under inert atmosphere. The resulting solution was stirred at room temperature for 1 h, then 25 mg (0.16 mmol) of ethyl iodide were added and the reaction mixture stirred for additional 24h at room temperature. The reaction mixture was diluted with 10 ml of 10% NH4CI water solution and product extracted with ethyl acetate (3x 10 ml). The organic phase was dried over Na2SO4 and evaporated under reduced pressure. Crude product was purified by column chromatography over silica gel (ethyl acetate 5: methanol 1 , Rf=0.25) yielding colorless foam (31 mg, 30%). 1HNMR (500 MHz, CDCI3) δ: 7.3 (m, 4.5H), 7.25-7.0 (m, 3H), 6.9, 6.7 (2xbs, 0.6H), 3.9 (bs, 0.6H), 3.5 (dd, J=12.97, 9.92 Hz, 1 H), 3.4 (m, 3.5 H), 3.2 (bs, 1 H), 3.0-2.7 (m, 3H), 2.7 (s, 3H), 2.5 (bs, 4H), 2.4-1.6 (m, 10H), 1.5 (s, 4H), 1 ,4 (s, 2H), 1.1 (bs, 3H). 13CNMR (125MHz, CDCI3) δ: 173.0, 172.0, 136.3, 130.6, 130.2, 129.5, 128.4, 127.2, 126.8, 66.4, 56.2, 55.9, 53.4, 51.7, 51.1 , 50.6, 47.3, 44.6, 44.1 , 42.5, 41.6, 41.1 , 38.8, 36.0, 34.0, 33.5, 30.2, 29.7, 29.4, 26.9, 25.1 , 1 1.7. LC-MS: M+1 =587. Retention time: 5.59 min (API).
Example 14: synthesis of 4-({[(2S)-2-(3,4-dichlorophenyl)-4-{4'-[(dimethylamino)- carbonyli-1 ,4'-bipiperidin-1 '-vDbutylKmethvDaminojcarbonvDphenyl acetate (example compound 5)
Figure imgf000072_0001
Here: synthesis of fert-butyl [(2S)-2-(3,4-dichlorophenyl)-4-{4'-[(dimethylamino)- carbonyl1-1 ,4'-bipiperidin-1 '-yl)butyl1methyl carbamate as starting material
Figure imgf000072_0002
To a suspension of 4 g (0.01 15 mol) [2-(3,4-Dichloro-phenyl)-4-oxo-butyl]- methyl-carbamic acid tert-butyl ester, 4.35 g (0.0139 mol) of the piperidinopiperidineketamide hydrochloride [1 ,4']Bipiperidinyl-4'-carboxylic acid dimethylamide and 2 g of sodium acetate in 200 ml of THF, 1.5 ml of acetic acid were added. The reaction mixture was stirred for 4 hours at room temperature. To the reaction mixture were the added portion-wise 4.88 g (0.0231 mol) of sodium triacetoxyborohydride and the solution was stirred for 15 hours at room temperature and subsequently concentrated to dryness. The remaining material was dissolved in 100 ml of MTBE and 5 g of potassium hydroxide in 50 ml of water. The separated organic layer was then washed three times with 50 ml water, dried on sodium sulphate and concentrated to deliver 6.06 g of a foam which was used in the next step without further purification. Yield: 92%
Here: synthesis of 1 '-[(3S)-3-(3,4-dichlorophenyl)-4-(methylamino)butyl1-Λ/,Λ/-dimethyl- 1 ,4'-bipiperidine-4'-carboxamide as starting material
Figure imgf000073_0001
6 g (0.0105 mol) of [2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']- bipiperidinyl-1'-yl)-butyl]-methyl-carbamic acid tert-butyl ester were dissolved in 10 ml methylene chloride and 40 ml of of 5N solution of HCI in isopropanol (0.2 mol) at room temperature. A precipitate of 1 '-[(3S)-3-(3,4-dichlorophenyl)-4-(methylamino)butyl]- Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-4'-carboxamide as hydrochloride precipitated and the mixture was stirred for 15 hours till completeness of the reaction. The mixture was dropped in 150 ml MTBE and further stirred for 1 hour at room temperature. The precipitate was separated by filtration, washed 3 times with 10 ml of MTBE and the obtained solid dried under vacuum at 600C to deliver 4.1 g of 1 '-[(3S)-3-(3,4- dichlorophenyl)-4-(methylamino)butyl]-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-4'-carboxamide as trihydrochloride. Yield: 67%. Optical rotation: -2.0°(c=1 % in methanol)
Here: synthesis of 4-({[(2S)-2-(3,4-dichlorophenyl)-4-{4'-[(-Λ/,Λ/-dimethylamino)- carbonyl11 ,4'-bipiperidin-1 '-yl)butyl1(methvDamino)carbonyl)phenyl acetate
Figure imgf000074_0001
220 mg (0.00038 mol) of 1 '-[(3S)-3-(3,4-dichlorophenyl)-4-(methylamino)butyl]-Λ/,Λ/- dimethyl-1 ,4'-bipiperidine-4'-carboxamide were dissolved in 20 ml of methylene chloride in the presence of 200 μl of triethylamine under stirring at room temperature. To the reaction mixture, were added drop wise at room temperature, a solution of 98 mg of 4-acetoxybenzoyl chloride in 20 ml of methylene chloride and subsequently 200 μl of triethylamine were added. The reaction mixture was stirred for 15 hours at room temperature and concentrated in vacuum. The residue was dissolved in 50 ml of ethyl acetate and 30 ml of MTBE in the presence of 200 mg potassium hydroxide dissolved in 20 ml of water. The organic phase was separated and washed 4 times with 20 ml of water. The organic layer was recovered, dried on sodium sulphate and concentrated to dryness to deliver 240 mg (quantitative yield) of 4-({[(2S)-2-(3,4-dichlorophenyl)-4-{4'- [(dimethylaminoJcarbonyll-i ^'-bipiperidin-i '-ylJbuty^methyOaminoJcarbonyOphenyl acetate as a glassy material.
1HNMR(as base) (500 MHz, CDCI3 ) δ: 7.45-7.1 (m, 7H), 7.0, 6.8 (2xbs, 0.7H), 3.82 (bs, 0.7H), 3.55 (dd, 1 H), 3.5-3.2 (m, 4 H), 3.1 (bs, 0.7 H), 3.0 (m, 2H), 2.95-2.90 (2xs, 3H), 2.8-2.5 (m, 4.5H),2.3 (s, 3H) 2.25-1.6 (m, 12H), 1.5 (s, 4H), 1 ,4 (s, 2H). 13CNMR (125MHz, CDCI3 ) δ: 170.7, 168.2, 150.7, 131.7., 121.5, 120.9, 66.1 , 55.2, 56.1 , 52.6, 51.7, 50.9, 50.4, 46.6, 40.9, 38.0, 36.9, 29.9, 26.2, 24.4, 20.4 LC-MS: M+1 (monoisotope): 631. Retention time: 7.78 min (API).
Example 15: Synthesis of 1 '-f(3S)-3-(3,4-dichlorophenyl)-4-[(4-hvdroxybenzoyl)-
(methyl)amino1butyl)-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-4'-carboxamide (example compound 6)
Figure imgf000075_0001
170 mg (0.00027 mol) of 4-({[(2S)-2-(3,4-dichlorophenyl)-4-{4'-[(dimethylamino)- carbonyl]-1 ,4'-bipiperidin-1 '-yl}butyl](methyl)amino}carbonyl)phenyl acetate was dis- solved in 30 ml of methanol in the presence of 300 mg of potassium hydroxide at room temperature and stirred for 20 hours. The solution was then concentrated to dryness and dissolved in 50 ml of ethyl acetate, 40 ml of MTBE and a solution of 2 g of ammonium chloride in 20 ml of water until a pH7 was reached. The organic phase was separated, washed 3 times with 20 ml of water, dried on sodium sulphate, concentrated under vacuum to deliver 102 mg of 1 '-{(3S)-3-(3,4-dichlorophenyl)-4-[(4- hydroxybenzoyl)(methyl)amino]-butyl}-Λ/,Λ/-dimethyl-1 ,4'-bipiperidine-4'-carboxamide as a glassy compound (yield: 64%).
1HNMR(as base) (500 MHz, CDCI3) δ: 7.40-6.70 (m, 7H), (2xbs, 0.7H), 3.88 (bs, 0.7H), 3.45 (dd, 1 H), 3.5-3.25 (m, 4. H), 3.2 (bs, 0.7 H), 3.0 (m, 2H), 2.95-2.90 (2xs, 3H), 2.8-
2.5 (m, 4.5H), 2.4-1.6 (m, 12H), 1.5 (s, 4H), 1 ,4 (s, 2H).
13CNMR (125MHz, CDCI3) δ: 173.5, 172.8,172.4, 160.1 , 158.8, 132.9, 131.56, 131.4,
130.9, 129.8, 127.1 , 70.6, 65.9, 55.6, 53.4, 51.7, 47.3, 38.7, 37.8, 31.9, 26.7, 26.0,
24.9 LC-MS: M+1 (monoisotope): 589.
Retention time:7.06 min (API).
Example 16: Synthesis of 1 '-[(3S)-4-[benzoyl(methyl)amino1-3-phenylbutyl1-Λ/,Λ/- dimethyl-1 ,4'-bipiperidine-4'-carboxamide
Figure imgf000076_0001
700 mg (0.00108 mol) of 1 '-[4-(benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid methylamide dihydrochloride were dissolved in 100 ml ethanol at room temperature. To the solution were added 50 ml of water and 560 mg of potassium hydroxide. The solution was hydrogenated for 5 days at room temperature in the presence of 5 spatules of 10% palladium on charcoal at 4 bars. The solution was recovered after filtration and separation of the catalyst, concentrated to dryness and subsequently dissolved in 60 ml MTBE. The organic phase was washed 3 times with 10 ml of water, separated, dried on sodium sulphate and concentrated to dryness to deliver the title product as 405 mg of an oily material (Yield: 74%). 390 mg of the base were dissolved in 2 ml of ethanol at 400C and 330 μl of HCI 5N in IPA were added under stirring to give a solution to whom 20 ml of MTBE were added to deliver a precipitate. After heating of the solution to 500C, the suspension was cooled down to room temperature. The precipitate was recovered by filtration, washed twice with 10 ml of methanol, dissolved in methanol the concentration to dryness of which delivered 435 mg (98% yield) of a foamy colourless dihydrochloride.
1HNMR(as base) (500 MHz, CDCI3) δ: 7.40-6.85 (m, 10H), 3.87 (bs, 0.7H), 3.58 (dd, 0.7H), 3.5-3.25 (m, 4.4 H), 3.1 (bs, 0.7 H), 2.96 (m, 2H), 2.95-2.85 (bs, 3H), 2.85-2.45
(m, 4.5H), 2.3-1.6 (m, 12H), 1.51 (s, 4H), 1 ,41 (s, 2H).
13CNMR (125MHz, CDCI3) δ: 173.5, 171.5, 142.4, 136.8., 129.2, 128.7,128.5,
128.2,128.0, 126.7, 66.9, 57.6, 56.4, 53.4, 51.8, 47.3, 42.4, 38.5, 37.7, 33.6, 31.1 ,
26.9, 25.1 LC-MS: M+1 (monoisotope): 505.
Retention Time: 4.94 min (API). Examples 17 to 36
Compounds 105 to 123 were obtained by reductive amination as outlined in process (a). An aldehyde is reductive aminated with an amine to yield compound of Formula I, examples 105 to 123
Figure imgf000077_0001
Synthesis of Λ/-[(2S)-4-{4-[(cvclopropylmethyl)(propionyl)-amino1piperidin-1 -yl)-2-(3,4- dichlorophenyl)butyl1-Λ/-methylbenzamide (example compound 105)
Figure imgf000077_0002
To a mixture of 105 mg (0.3 mmol) of N-[2-(3,4-Dichloro-phenyl)-4-oxo-butyl]-N- methyl-benzamide (compound II), 70 mg (0.33 mmol) of N-(cyclopropylmethyl)-N- piperidin-4-ylpropanamide (compound III), and 37 mg (0.45 mmmol) sodium acetate in 6 ml THF at room temperature under stirring were added in 0.03 ml (0.51 mmol) acetic acid. After 0.5 h stirring, 127 mg (0.6 mmol) of sodium triacetoxyborohydride were added to this mixture. After stirring for further15 h, the mixture was concentrated under vacuum to dryness and re-dissolved in 20 ml of dichloromethane. The organic solution was washed three times with potassium hydrogen carbon ate and then dried on sodium sulfate. After filtration the organic phase was concentrated under vacuum to dryness. The crude product was purified by column chromatography on silica gel using ethyl acetate / ethanol as eluents (100/0 to 80/20 v/v) yielding 93 mg of a colorless oil. The following compounds were prepared according to the described process of reductive amination:
N-[(2S)-2-(3,4-dichlorophenyl)-4-{4-[isopropyl(propionyl)amino]piperidin-1- yl}butyl]-N-methylbenzamide (compound example 106); Λ/-[(2S)-2-(3,4-dichlorophenyl)- 4-{4-[phenyl(propionyl)amino]piperidin-1-yl}butyl]-Λ/-methylbenzamide (compound example 107); Λ/-[(2S)-4-{4-[butyl(propionyl)amino]piperidin-1 -yl}-2-(3,4-dichloro- phenyl)butyl]-Λ/-methylbenzamide (compound example 108); Λ/-[(2S)-4-{4-[butyl- (cyclopropylcarbonyl)amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-Λ/-methyl- benzamide (compound example 109); Λ/-[(2S)-4-{4-[butyl(cyclohexylcarbonyl)- amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-Λ/-methylbenzamide (compound example 1 10); Λ/-[(2S)-4-{4-[benzoyl(butyl)amino]piperidin-1-yl}-2-(3,4-dichloro- phenyl)butyl]-Λ/-methylbenzamide (compound example 1 1 1 ); N-[(2S)-2-(3,4- dichlorophenyl)-4-{4-[(4-methoxybutyl)(propionyl)amino]piperidin-1-yl}butyl]-N- methylbenzamide (compound example 1 12); Λ/-[(2S)-4-{4-[(cyclopropylcarbonyl)(4- methoxybutyl)amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-Λ/-methylbenzamide
(compound example 1 13); Λ/-[(2S)-4-{4-[(cyclohexylcarbonyl)(4-methoxybutyl)- amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-Λ/-methylbenzamide (compound example 1 14); N-[(2S)-4-{4-[benzoyl(4-methoxybutyl)amino]piperidin-1-yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide (compound example 1 15); N-[(2S)-4-{4- [cyclohexyl(propionyl)amino]piperidin-1 -yl}-2-(3,4-dichlorophenyl)butyl]-N-methyl- benzamide (compound example 1 16); N-[(2S)-4-{4-[cyclohexyl(cyclopropylcarbonyl)- amino]piperidin-1-yl}-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide (compound example 1 17); N-[(2S)-4-{4-[cyclohexyl(cyclohexylcarbonyl)amino]piperidin-1-yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide (compound example 1 18); N-[(2S)-4-{4- [benzoyl(cyclohexyl)amino]piperidin-1 -yl}-2-(3,4-dichlorophenyl)butyl]-N-methyl- benzamide (compound example 1 19); N-[(2S)-2-(3,4-dichlorophenyl)-4-{4-[(1-methyl- piperidin-4-yl)(propionyl)amino]piperidin-1-yl}butyl]-N-methylbenzamide (compound example 120); N-[(2S)-4-{4-[(cyclopropylcarbonyl)(1-methylpiperidin-4-yl)amino]- piperidin-1 -yl}-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide (compound example 121 ); N-[(2S)-4-{4-[(cyclohexylcarbonyl)( 1 -methylpiperidin-4-yl)amino]piperidin-1 -yl}-2-
(3,4-dichlorophenyl)butyl]-N-methylbenzamide (compound example 122); and N-{1- [(3S)-4-[benzoyl(methyl)amino]-3-(3,4-dichlorophenyl)butyl]piperidin-4-yl}-N-(1- methylpiperidin-4-yl)benzamide (compound example 123).
Example 37: Preparation of starting materials (compound III):
Figure imgf000079_0001
MId IMc
amination
Figure imgf000079_0002
Ilia 1Mb
deprotection
Figure imgf000079_0003
Commercially available compound IHd is reacted with tertiary butoxycarbonyl anhydride to deliver compound INc which is then is transformed to intermediate 1Mb under conditions of reductive amination. Intermediate 1Mb is acylated to the corresponding amide Ilia. Amide Ilia is then deprotected to yield intermediate III.
Example 38: Preparation of Λ/-(cyclopropylmethyl)-Λ/-piperidin-4-ylpropanamide
Figure imgf000079_0004
To a mixture of 1 g (5 mmol) of fert-butyl 4-oxopiperidine-1-carboxylate (compound INc), 0.39 ml (4.5 mmol) of 1-cyclopropylmethanamine and 0.56 g (6.8 mmmol) sodium acetate in 20 ml THF at room temperature under stirring were added 0.44 ml (7.75 mmol) acetic acid. After 1 h stirring 1.93 g (9.1 mmol) of sodium triacetoxyborohydride were added to this mixture. After stirring for further 15 h the mixture was concentrated under vacuum to dryness and re-dissolved in 50 ml of ether. The organic solution was extracted three times with 30 ml of 0.1 n aqueous HCI. The combined water layers were alkalized by aqueous sodium hydroxide and then extracted three times with 30 ml of ether. The combined organic phase was dried on sodium sulfate, filtered and concentrated to dryness under vacuum to give 1.1 g crude fert-butyl 4-[(cyclopropylmethyl)amino]piperidine-1-carboxylate (1Mb).
To a 5°C cold solution of 1.1 g (4.3 mmol) of crude crude ferf-butyl A- [(cyclopropylmethyl)-amino]piperidine-1-carboxylate (compound INb) and 1.13 ml (6.5 mmol) N-ethyl-diisopropylamine in 25 ml dichloromethane, 0.45 ml (5.2 mmol) propanoyl chloride in 3 ml dichloromethane were added. After stirring for 2 h the mixture was evaporated and redissolved in 50 ml ether. The organic phase was sequentially washed 2 times with 30 ml water, 2 times with 20 ml of 0.1 N aqueous sodium hydroxide, with 30 ml of 0.1 N aqueous hydrochloric acid, dried on sodium sulfate and concentrated to give 1.1 g of crude fert-butyl A- [(cyclopropylmethyl)(propionyl)amino]cyclohexane-carboxylate (compound Ilia).
The solution of 1.1 g of fert-butyl 4-[(cyclopropylmethyl)(propionyl)amino]- piperidine-1-carboxylate (compound Ilia) in 20 ml 4M hydrogen chloride in dioxane and 5 ml ethanol was stirred at room temperature for 15 h, then evaporated and re- dissolved in 50 ml dichloromethane and sequentially washed 3 times with 20 ml of aqueous potassium carbonate (10 %), with 30 ml water, dried on sodium sulfate and concentrated under vacuum to yield 0.45 g of Λ/-(cyclopropylmethyl)-Λ/-piperidin-4- ylpropanamide (compound III) as colourless oil.
The preparation of the required series of 4-substituted piperidines (see above) was performed according to the described process.
The compounds of formula I listed in table 14 below were prepared according to the process described in the above examples or according to processes analogous thereto. ormula I
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Table 16 contains analytical data from mass spectroscopy indicating the retention time in relation to the molecular weight observed.
Table 16: MS data and retention time
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Example 39:
Capsules containing 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
Capsules with the following composition per capsule were produced:
1'-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide 20 mg
Corn starch 60 mg Lactose 300 mg Ethyl acetate q.s.
The active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate. The paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent. The dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
Talcum 5 mg
Magnesium stearate 5 mg Corn starch 9 mg
and then poured into 400 mg capsules (= capsule size 0).
Example 40:
Capsules containing 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid methylamide Capsules with the following composition per capsule were produced:
1'-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid methylamide 20 mg
Corn starch 60 mg
Lactose 300 mg
Ethyl acetate q.s.
The active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate. The paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent. The dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
Talcum 5 mg
Magnesium stearate 5 mg
Corn starch 9 mg
and then poured into 400 mg capsules (= capsule size 0).
Example 41 :
Capsules containing 1 '-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4-dichloro- phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
Capsules with the following composition per capsule were produced:
1'-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide 20 mg
Corn starch 60 mg
Lactose 300 mg
Ethyl acetate q.s.
The active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate. The paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent. The dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
Talcum 5 mg
Magnesium stearate 5 mg
Corn starch 9 mg
and then poured into 400 mg capsules (= capsule size 0).
Example 42:
Capsules containing 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
Capsules with the following composition per capsule were produced:
1'-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide 20 mg
Corn starch 60 mg
Lactose 300 mg
Ethyl acetate q.s.
The active substance, the corn starch and the lactose were processed into a homogenous pasty mixture using ethyl acetate. The paste was ground and the resulting granules were placed on a suitable tray and dried at 45°C in order to remove the solvent. The dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries:
Talcum 5 mg
Magnesium stearate 5 mg
Corn starch 9 mg
and then poured into 400 mg capsules (= capsule size 0).

Claims

Claims
Compounds of general formula I
Figure imgf000096_0001
wherein
R1 is selected from the group consisting of: alkyl and cycloalkyl;
R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring;
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m NR9R10, and NR7R8;
R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and (CO)mNR9R10;
R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6- membered ring, none of the ring atoms is replaced by carbonyl;
R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and physiologically compatible acid addition salts of compounds of Formula I.
2. Compounds according to Claim 1 wherein R1 is methyl.
3. Compounds according to any of Claims 1 or 2 wherein R3 and R4 are independently selected from the group consisting of: hydrogen, fluoro, chloro, preferably hydrogen or chloro.
4. Compounds according to any of the preceding claims wherein X is CR6, wherein R5 is NR7R8, and wherein R6 is (CO)mNR9R10 with m =1.
5. Compounds according to any of the preceding claims wherein X is N, wherein R5 is cycloalkyl substituted with (CO)mNR9R10 and m =1 .
6. Compounds according to any of the preceding claims wherein R7 and R8 form together a 6-membered ring or wherein R7 and R8 form together a 6- membered ring substituted by CONR9R10.
7. Compounds according to any of the preceding claims wherein R9 and R10 are both methyl, or wherein R9 and R10 form together a 6-membered ring, or wherein R9 and R10 form together a 5-membered ring substituted by carbonyl.
8. Compounds according to any of the preceding claims wherein R2 is selected from the group consisting of:
Ci to C20 alky I; C3 to C20 cycloalkyl; C2 to C20 alkenyl;
Figure imgf000097_0001
Figure imgf000098_0001
wherein each of R1 1 to R16 are independently selected from the group consisting of: hydrogen, fluoro, chloro, bromo, hydroxyl, alkoxy, cyano,
N(H)C(O)Oalkyl, aminoalkyl, dialkylamino, OCF3, CF3, carboxyalkyl, S(O)2NH2, phenyl, alkyl, and cycloalkyl; wherein each of R18 and R19 are independently selected from the group consisting of: hydrogen, cyano and aryl; wherein t is 0 or 1 ; wherein each Q is independently selected from the group consisting of: CR1 1 and N; wherein Y is selected from the group consisting of: CH, N and NO; wherein Z is selected from the group consisting of: C-benzyl, NH, N-benzyl, N- alkyl, O and S; wherein each V is independently selected from the group consisting of: N and
CR17; and; wherein R17 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, and thioalkyl.
Compounds according to any of the preceding claims wherein R5 is selected from the group consisting of:
Figure imgf000099_0001
10. Compounds according to any of the preceding claims selected from the group consisting of: 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide;
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid methylamide;
1 '-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
Acetic acid 4-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-hydroxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide;
Acetic acid 2-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester;
1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,5-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-1 -carbonyl-3-cyano)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2,3,4-trifluoro-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 -oxy-pyridine-4-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(6-Chloro-pyridine-3-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-3-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Benzyl-2-methylsulfanyl-3H-imidazole-4-carbonyl)-methyl-amino]-3-
(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-oxo-2-phenyl-4H-chromene-3- carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-(Cyclopropanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-(Cyclopentanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methylamino-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; N-[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)- butyl]-N-methyl-phthalamic acid;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methoxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(Biphenyl-4-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,3-diphenyl-propionyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-(3-(3,4-Dichloro-phenyl)-4-{[3-(4-hydroxy-phenyl)-propionyl]-methyl-amino}- butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 -methyl-1 H-pyrrole-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(2-Biphenyl-4-yl-acetyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-{[3-(4-Chloro-phenyl)-acryloyl]-methyl-amino}-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 H-pyrrole-2-carbonyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-3-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-indole-3-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-1 H-indol-3-yl-acetyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-indole-5-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyrazine-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-2-carbonyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-4-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-oxo-4H-chromene-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-sulfamoyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(4-Chloro-3-sulfamoyl-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-1 H-imidazol-4-yl-acetyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl-acetyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-4-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(1 -Acetyl-piperidine-4-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(tetrahydro-pyran-4-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
(4-{[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)- butyl]-methyl-carbamoyl}-phenyl)-carbamic acid tert-butyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl-methoxy}-benzoyl)-methyl- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide
1 '-(3-(3,4-Dichloro-phenyl)-4-{[2-(2,4-di{trifluoromethyl}-phenyl)-acetyl]-methyl- amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-(3-(3,4-Dichloro-phenyl)-4-{[2-(2,6-dihydroxy-pyrimidin-4-yl)-acetyl]-methyl- amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 4-{[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipipericlinyl-1 '-yl)- butyl]-methyl-carbamoyl}-pipericline-1 -carboxylic acid tert-butyl ester;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-imidazole-4-carbonyl)-metriyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; (1 -{[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)- butyl]-methyl-carbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester;
[2-(3,4-Dichloro-phenyl)-4-(4'-dimetriylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)-butyl]- methyl-carbamic acid tert-butyl ester;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furazan-3-carbonyl)-metriyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,2-difluoro-benzo[1 ,3]dioxole-5-carbonyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 H-pyrrole-3-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-(3-(3,4-Dichloro-phenyl)-4-{[3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carbo- nyl]-methyl-amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-(3-(3,4-Dichloro-phenyl)-4-{[5-(4-methoxy-phenyl)-oxazole-4-carbonyl]- methyl-amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1 -phenyl-1 H-[1 ,2,3]triazole-4- carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-benzo[b]thiophene-2-carbonyl)- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3,5-Bis-trifluoromethyl-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(2-Bromo-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[3-(3,4-Dichloro-phenyl)-4-(methyl-pentafluorobenzoyl-amino)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,6-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(2,6-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-trifluoromethyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(3,4-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-methoxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(3-trifluoromethyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(4-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methoxy-benzoyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-trifluoromethyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methyl-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,2-dimethyl-propionyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-[3-(3,4-Dichloro-phenyl)-4-(methyl-phenylacetyl-amino)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-phenyl-cyclopropanecarbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(4-Cyano-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-1 -carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-(Benzoyl-methyl-amino)-3-phenyl-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid ethyl-methyl-amide;
N-{2-(3,4-Dichloro-phenyl)-4-[4-(1 -dimethylcarbamoyl-cyclohexyl)-piperazin-1 - yl]-butyl}-N-methyl-benzamide;
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-2- carboxylic acid dimethylamide;
1 -[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-4-pyrrolidin-1 -yl-piperidine-4-carboxylic acid dimethylamide;
1 -[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-4-pyrrolidin-1 -yl- piperidine-4-carboxylic acid dimethylamide; N-[4-[4-(Cyclopropylmethyl-propionyl-amino)-piperidin-1 -yl]-2-(3,4-dichloro- phenyl)-butyl]-N-methyl-benzamide;
N-{2-(3,4-Dichloro-phenyl)-4-[4-(isopropyl-propionyl-amino)-piperidin-1 -yl]- butyl}-N-methyl-benzamide;
N-{2-(3,4-Dichloro-phenyl)-4-[4-(phenyl-propionyl-amino)-piperidin-1 -yl]-butyl}- N-methyl-benzamide; N-[4-[4-(Butyl-propionyl-amino)-piperidin-1 -yl]-2-(3,4-dichloro-phenyl)-butyl]-N- methyl-benzamide;
N-[4-[4-(Butyl-cyclopropanecarbonyl-amino)-piperidin-1 -yl]-2-(3,4-clichloro- phenyl)-butyl]-N-methyl-benzamicle; N-[4-[4-(Butyl-cyclohexanecarbonyl-amino)-piperidin-1 -yl]-2-(3,4-clichloro- phenyl)-butyl]-N-methyl-benzamide;
N-[4-[4-(Benzoyl-butyl-amino)-piperidin-1 -yl]-2-(3,4-dichloro-phenyl)-butyl]-N- methyl-benzamide;
N-(2-(3,4-Dichloro-phenyl)-4-{4-[(4-methoxy-butyl)-propionyl-amino]-piperidin-1 - yl}-butyl)-N-methyl-benzamide;
N-[4-{4-[Cyclopropanecarbonyl-(4-methoxy-butyl)-amino]-piperidin-1 -yl}-2-(3,4- dichloro-phenyl)-butyl]-N-methyl-benzamide;
N-[4-{4-[Cyclohexanecarbonyl-(4-methoxy-butyl)-amino]-piperidin-1 -yl}-2-(3,4- dichloro-phenyl)-butyl]-N-methyl-benzamide; N-[4-{4-[Benzoyl-(4-methoxy-butyl)-amino]-piperidin-1 -yl}-2-(3,4-dichloro- phenyl)-butyl]-N-methyl-benzamide;
N-[4-{4-[cyclohexyl(propionyl)amino]piperidin-1 -yl}-2-(3,4-dichlorophenyl)butyl]- N-methylbenzamide;
N-[4-{4-[cyclohexyl(cyclopropylcarbonyl)amino]piperidin-1 -yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide;
N-[4-{4-[cyclohexyl(cyclohexylcarbonyl)amino]piperidin-1 -yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide;
N-[4-{4-[benzoyl(cyclohexyl)amino]piperidin-1 -yl}-2-(3,4-dichlorophenyl)butyl]-N- methylbenzamide; N-[2-(3,4-dichlorophenyl)-4-{4-[(1 -methylpiperidin-4- yl)(propionyl)amino]piperidin-1 -yl}butyl]-N-methylbenzamide;
N-[4-{4-[(cyclopropylcarbonyl)(1 -methylpiperidin-4-yl)amino]piperidin-1 -yl}-2- (3,4-dichlorophenyl)butyl]-N-methylbenzamide;
N-[4-{4-[(cyclohexylcarbonyl)(1 -methylpiperidin-4-yl)amino]piperidin-1 -yl}-2-(3,4- dichlorophenyl)butyl]-N-methylbenzamide; N-{1 -[4-[benzoyl(methyl)amino]-3-(3,4-clichlorophenyl)butyl]pipericlin-4-yl}-N-(1 - methylpiperidin-4-yl)benzamide;
N-{2-(3,4-Dichloro-phenyl)-4-[4'-(pyrrolidine-1 -carbonyl)-[1 ,4']bipiperidinyl-1 '-yl]- butyl}-N-methyl-benzamide; 1 -[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-4-(2-oxo-pyrrolidin-1 -yl)-piperidine-4-carboxylic acid dimethyl-amide;
3-Cyano-naphthalene-1 -carboxylic acid {2-(3,4-dichloro-phenyl)-4-[4'- (piperidine-1 -carbonyl)-[1 ,4']bipiperidinyl-1 '-yl]-butyl}-methyl-amide;
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid di-propylamide;
1 -[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-prienyl)-butyl]-4-morpriolin -4-yl-piperidine-4-carboxylic acid dimethylamide;
1 -[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-prienyl)-butyl]-4-pyrrolidin-1 -yl- piperidine-4-carboxylic acid isopropyl-methyl-amide; N-{2-(3,4-Dichloro-phenyl)-4-[4-(piperidine-1 -carbonyl)-4-pyrrolidin-1 -yl- piperidin-1 -yl]-butyl}-N-methyl-benzamide;
1 -[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-prienyl)-butyl]-4-pyrrolidin-1 -yl- piperidine-4-carboxylic acid diethylamide;
N-{2-(3,4-Dichloro-phenyl)-4-[4-(morpholine-4-carbonyl)-4-pyrrolidin-1 -yl- piperidin-1 -yl]-butyl}-N-methyl-benzamide; and physiologically compatible acid addition salts of these compounds.
Compounds according to Claim 10 selected from the group consisting of:
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide;
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid methylamide;
1 '-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
Acetic acid 4-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-riydroxy-benzoyl)-metriyl-amino]-butyl}-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide;
Acetic acid 2-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester;
1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dicriloro-prienyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,5-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-1 -carbonyl-3-cyano)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2,3,4-trifluoro-benzoyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(6-Chloro-pyridine-3-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-3-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Cyclopentanecarbonyl-methyl-amino)-3-(3,4-clichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methylamino-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; N-[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)- butyl]-N-methyl-phthalamic acid;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methoxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-(3-(3,4-Dichloro-phenyl)-4-{[3-(4-hydroxy-phenyl)-propionyl]-methyl-amino}- butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 -methyl-1 H-pyrrole-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-2-carbonyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(1 H-pyrrole-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(thiophene-3-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(1 H-indole-5-carbonyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-4-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-oxo-4H-chromene-2-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(4-sulfamoyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(4-Chloro-3-sulfamoyl-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-4-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(tetrahydro-pyran-4-carbonyl)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; (4-{[2-(3,4-Dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bipiperidinyl-1 '-yl)- butyl]-methyl-carbamoyl}-phenyl)-carbamic acid tert-butyl ester;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl-methoxy}-benzoyl)-methyl- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide
1 '-(3-(3,4-Dichloro-phenyl)-4-{[2-(2,4-di{trifluoromethyl}-phenyl)-acetyl]-methyl- amino}-butyl)-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,2-difluoro-benzo[1 ,3]dioxole-5-carbonyl)- methyl-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1 -phenyl-1 H-[1 ,2,3]triazole-4- carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(2-Bromo-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,6-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-[4-[(2,4-Dichloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-trifluoromethyl-benzoyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-methyl-benzoyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(3-Chloro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-methoxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(3-trifluoromethyl-benzoyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-methyl-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(4-Cyano-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-(Benzoyl-methyl-amino)-3-phenyl-butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid ethyl-methyl-amide;
N-{2-(3,4-Dichloro-phenyl)-4-[4-(1 -dimethylcarbamoyl-cyclohexyl)-piperazin-1 - yl]-butyl}-N-methyl-benzamide;
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-2- carboxylic acid dimethylamide; 1 -[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-clichloro-phenyl)- butyl]-4-pyrrolidin-1 -yl-piperidine-4-carboxylic acid dimethylamide;
1 -[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-4-pyrrolidin-1 -yl- piperidine-4-carboxylic acid dimethylamide; and physiologically compatible acid addition salts of these compounds.
12. Compounds according to Claim 10 selected from the group consisting of:
1 '-[4-(Benzoyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-[1 ,4']bipiperidinyl-4'- carboxylic acid dimethylamide; 1 '-[4-(Cyclohexanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-fluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
Acetic acid 4-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(4-hydroxy-benzoyl)-methyl-amino]-butyl}-[1 ,4']bi- piperidinyl-4'-carboxylic acid dimethylamide;
Acetic acid 2-{[2-(3,4-dichloro-phenyl)-4-(4'-dimethylcarbamoyl-[1 ,4']bi- piperidinyl-1 '-yl)-butyl]-methyl-carbamoyl}-phenyl ester; 1 '-[4-[(3-Chloro-4-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,5-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(5-Chloro-2-fluoro-benzoyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(naphthalene-1 -carbonyl-3-cyano)-amino]- butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(2-hydroxy-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid diethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3,4-difluoro-benzoyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[(2,5-difluoro-benzoyl)-methyl-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(6-Chloro-pyridine-3-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-(Cyclopentanecarbonyl-methyl-amino)-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(furan-2-carbonyl)-methyl-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(pyridine-2-carbonyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-2-yl-acetyl)-amino]-butyl}-
[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(2-pyridin-3-yl-acetyl)-amino]-butyl}- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[(3-{trifluoromethyl-methoxy}-benzoyl)-methyl- amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-{3-(3,4-Dichloro-phenyl)-4-[methyl-(5-methyl-1 -phenyl-1 H-[1 ,2,3]triazole-4- carbonyl)-amino]-butyl}-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 '-[4-[(Benzofuran-5-carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)-butyl]- [1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide; 1 '-[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-[1 ,4']bipiperidinyl-4'-carboxylic acid dimethylamide;
1 -[4-[(3-Cyano-naphthalene-1 -carbonyl)-methyl-amino]-3-(3,4-dichloro-phenyl)- butyl]-4-pyrrolidin-1 -yl-piperidine-4-carboxylic acid dimethylamide; and physiologically compatible acid addition salts of these compounds.
13. A pharmaceutical composition comprising
(a) a pharmacologically effective quantity of a compound of Formula I,
Figure imgf000114_0001
consisting of: alkyl and cycloalkyl;
R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring;
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m NR9R10, and NR7R8;
R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and (CO)mNR9R10;
R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6-membered ring, none of the ring atoms is replaced by carbonyl; R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; their physiologically acceptable acid addition salts; and (b) conventional pharmaceutically acceptable auxiliaries and/or carriers.
14. A process for the preparation of compounds of general formula I
Figure imgf000115_0001
wherein
R1 is selected from the group consisting of: alkyl and cycloalkyl;
R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring; R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m
NR9R10, and NR7R8; R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and (CO)mNR9R10; R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6-membered ring, none of the ring atoms is replaced by carbonyl;
R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and their physiologically acceptable acid addition salts; characterized in that (a) compounds of formula I are prepared by reacting a compound of formula Il
Figure imgf000116_0001
with a compound of formula III
Figure imgf000116_0002
to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt; or,
(b) compounds of formula I are prepared by reacting a compound of formula III
Figure imgf000116_0003
with a compound of general formula IV
Figure imgf000117_0001
to give a compound of the general formula V,
Figure imgf000117_0002
compound of general formula V is then hydrolyzed in an acidic medium to give a compound of general formula Vl,
compound of general formula Vl is then reacted with a compound of formula VII
O
R2 Λ Cl VN
to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt; (C) compounds of formula I are prepared by reacting a compound of formula X
Figure imgf000118_0001
wherein Q is selected from the group consisting of: halogen, preferably, bromo or iodo; and methylsulfonyl; with a compound of formula III
Figure imgf000118_0002
to result in a compound of general formula I which is optionally converted into its physiologically compatible acid addition salt.
15. The use of compounds according to any of Claims 1 to 12 for the preparation of pharmaceutical preparations for the treatment and/or prophylaxis of any pathology where either neurokinin A and/or NK.sub.2 receptors, or neurokinin B and/or NK. sub.3 receptors, or both neurokinin A and neurokinin B and/or
NK.sub.2 and NK.sub.3 receptors are involved.
16. The use of compounds according to any of Claims 1 to 12 wherein R2 is a cyano-substituted naphthalene ring system, for the preparation of pharmaceutical preparations for the treatment and/or prophylaxis of any pathology where either substance P and/or NK.sub.1 receptors, or neurokinin A and/or NK.sub.2 receptors, or neurokinin B and/or NK.sub.3 receptors, or any combination of two or all three substance P, neurokinin A and neurokinin B and/or NK.sub.1 , NK.sub.2 and NK.sub.3 receptors are involved.
17. The use according to any of Claims 15 or 16 for the treatment and/or prophylaxis of pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular system and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases.
18. The use according to any of Claims 15 to 17 for the treatment and/or prophylaxis of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large-cell lung cancers, diseases of the immune system, bipolar disorders; migraine; pain, anxiety, depression, cognitive disorders, stress-related somatic disorders, psychosis, in particular schizophrenia, mania, schizoaffective disorder and panic disorders.
19. A method of treating or preventing of any pathology where either neurokinin A and/or NK. sub.2 receptors, or neurokinin B and/or NK. sub.3 receptors, or both neurokinin A and neurokinin B and/or NK. sub.2 and NK. sub.3 receptors are involved in mammals and humans, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I,
Figure imgf000119_0001
wherein
R1 is selected from the group consisting of: alkyl and cycloalkyl;
R2 is selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkenylenearyl, heteroaryl, and heterocyclic ring; R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m NR9R10, and NR7R8;
R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and (CO)mNR9R10;
R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6- membered ring, none of the ring atoms is replaced by carbonyl; R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and physiologically compatible acid addition salts of compounds of Formula I.
20. A method of treating or preventing of any pathology where either substance and/or NK. sub.1 receptors, or neurokinin A and/or NK. sub.2 receptors, or neurokinin B and/or NK. sub.3 receptors, or any combination of two or all three substance P, neurokinin A and neurokinin B and/or NK. sub.1 , NK. sub.2 and
NK.sub.3 receptors are involved, in mammals and humans, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I,
Figure imgf000120_0001
wherein
R1 is selected from the group consisting of: alkyl and cycloalkyl;
R2 is a cyano-substituted naphthalene ring system;
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, and carboxyalkyl;
X is selected from the group consisting of: CR6 and nitrogen;
R5 is selected from the group consisting of: alkyl optionally substituted with (CO)mNR9R10, cycloalkyl optionally substituted with (CO)m NR9R10, and NR7R8; R6 is selected from the group consisting of: hydrogen, alkyl, cycloalkyl, and (CO)mNR9R10; R7 and R8 are independently selected from the group consisting of: alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, COalkyl, COaryl, or wherein R7 and R8 form together a 5- to 7-membered ring optionally containing an additional heteroatome, wherein such ring may be substituted by CONR9R10, and wherein in a 6- membered ring, none of the ring atoms is replaced by carbonyl;
R9 and R10 are independently selected from the group consisting of: hydrogen, alkyl, cycloalkyl, aryl, alkylenearyl, alkyleneoxyalkyl, or wherein R9 and R10 form together a 5- to 7-membered ring optionally containing an additional heteroatome; m is selected from 0 or 1 ; and physiologically compatible acid addition salts of compounds of Formula I.
21 . A method of treating or preventing according to Claim 18 wherein pathologies of the respiratory, gastrointestinal, urinary, immune and cardiovascular system and of the central nervous system as well as pain, migraine, inflammation, nausea and vomiting, and skin diseases, are involved.
22. A method of treating or preventing according to Claim 18 and/or wherein pathologies of respiratory diseases, in particular asthma, chronic obstructive pulmonary disease, chronic obstructive bronchitis, bronchitis, cough, and rhinitis; skin diseases, in particular inflammatory skin reactions, allergic skin reactions, and psoriasis; arthropathy diseases, in particular arthtitis, vasculitides and systemic lupus erythematosus; functional or inflammatory disorders in the gastrointestinal tract, in particular pseudomembranous colitis, gastritis, acute and chronic pancreatitis, ulcerative colitis, Crohn's disease and diarrhoe; bladder diseases such as cystitis and interstitial cystitis; cardiovascular diseases such as hypertension, treatment of cancer especially melanomas, gliomas, small-cell and large-cell lung cancers, diseases of the immune system, bipolar disorders; migraine; anxiety, depression, cognitive disorders, stress- related somatic disorders, psychosis, in particular schizophrenia, mania, schizoaffective disorder and panic disorders, are involved.
PCT/EP2007/050964 2006-02-01 2007-02-01 Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations WO2007088181A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07704286A EP1979319A1 (en) 2006-02-01 2007-02-01 Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations
AU2007211475A AU2007211475A1 (en) 2006-02-01 2007-02-01 Novel dual NK2/NK3-antagonists, pharmaceutical compositions comprising them and processes for their preparations
JP2008552803A JP2009525308A (en) 2006-02-01 2007-02-01 Novel NK2 / NK3-dual antagonist, pharmaceutical composition containing them, and method for producing them
CA002641817A CA2641817A1 (en) 2006-02-01 2007-02-01 Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101139.1 2006-02-01
EP06101139 2006-02-01

Publications (1)

Publication Number Publication Date
WO2007088181A1 true WO2007088181A1 (en) 2007-08-09

Family

ID=36564222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/050964 WO2007088181A1 (en) 2006-02-01 2007-02-01 Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations

Country Status (7)

Country Link
EP (1) EP1979319A1 (en)
JP (1) JP2009525308A (en)
CN (1) CN101374811A (en)
AU (1) AU2007211475A1 (en)
CA (1) CA2641817A1 (en)
RU (1) RU2008135123A (en)
WO (1) WO2007088181A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044054A1 (en) * 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
JP2010539126A (en) * 2007-09-14 2010-12-16 エフ．ホフマン−ラ ロシュ アーゲー Piperidine derivatives as NK3 receptor antagonists
JP2011512374A (en) * 2008-02-22 2011-04-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted indole derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020003A1 (en) * 1998-10-07 2000-04-13 Astrazeneca Ab Naphthalenecarboxamides as tachykinin receptor antagonists
WO2002094821A1 (en) * 2001-05-21 2002-11-28 Sanofi-Synthelabo Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97540C (en) * 1989-11-06 1997-01-10 Sanofi Sa Process for the preparation of therapeutically useful aromatically substituted piperidine and piperazine derivatives
JPH10251228A (en) * 1997-03-06 1998-09-22 Schering Plough Corp Piperidine derivative as neurokinin antagonist
CA2336806A1 (en) * 1998-07-10 2000-01-20 Keith Russell N-substituted naphthalene carboxamides as neurokinin-receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020003A1 (en) * 1998-10-07 2000-04-13 Astrazeneca Ab Naphthalenecarboxamides as tachykinin receptor antagonists
WO2002094821A1 (en) * 2001-05-21 2002-11-28 Sanofi-Synthelabo Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBERT JEFFREY S ET AL: "Design, synthesis and SAR of tachykinin antagonists: Modulation of balance in NK1/NK2 receptor antagonist activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, no. 18, 2002, pages 3972 - 3983, XP002984041, ISSN: 0022-2623 *
POULSEN, ANDERS ET AL: "A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN , 16(4), 273-286 CODEN: JCADEQ; ISSN: 0920-654X, 2002, XP008025903 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539126A (en) * 2007-09-14 2010-12-16 エフ．ホフマン−ラ ロシュ アーゲー Piperidine derivatives as NK3 receptor antagonists
JP2011512374A (en) * 2008-02-22 2011-04-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted indole derivatives
US9206156B2 (en) 2008-02-22 2015-12-08 Grünenthal GmbH Substituted indole derivatives
WO2010044054A1 (en) * 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
JP2012505263A (en) * 2008-10-14 2012-03-01 アクテリオン ファーマシューティカルズ リミテッド Phenethylamide derivatives and their heterocyclyl analogs

Also Published As

Publication number Publication date
CN101374811A (en) 2009-02-25
CA2641817A1 (en) 2007-08-09
RU2008135123A (en) 2010-03-10
JP2009525308A (en) 2009-07-09
AU2007211475A1 (en) 2007-08-09
EP1979319A1 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
KR100413150B1 (en) Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
US20040006081A1 (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
US5116846A (en) N-aralkyl piperidine derivatives as psychotropic drugs
US4791112A (en) N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
JP2010520876A (en) Piperazine and piperidine mGluR5 potentiator
KR20010043032A (en) 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
CZ295557B6 (en) Piperidinylidene derivative, process and intermediate for its preparation, diagnostic agent, and pharmaceutical composition containing such derivative
WO2003103669A1 (en) 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
KR19990023604A (en) CsA-3 receptor antagonist
KR101429779B1 (en) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
US4912109A (en) N-heterocyclic-N-(4-piperidinyl) amides and pharmaceutical compositions and methods employing such compounds
CZ342397A3 (en) Piperazine derivatives as neurokinin antagonists
EP1979319A1 (en) Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations
NO309813B1 (en) Novel 1-acylpiperidine compounds, pharmaceutical preparations containing them, and their use in the treatment of diseases which show a response to antagonization of the NK1 receptor
JP2004277319A (en) 1-(4-piperidinylmethyl)piperidinylamide derivative and medicinal composition containing the same
US20070219214A1 (en) Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation
JP2005104896A (en) 2-alkoxy-6-amino-5-halogenopyridine-3-carboxamide derivative and pharmaceutical composition containing the same
JP2008088057A (en) N-substituted-n-(4-piperidinyl)amide derivative
KR101189031B1 (en) Spiropiperidine derivatives as nk3 antagonists
JP2001122784A (en) Pharmaceutical comprising 1-[(1-substituted-4-piperidinyl) methyl]-4-piperidine derivative
JP2007197428A (en) Pharmaceutical composition
BG108332A (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety and gastrointestinal disorders
US4900738A (en) N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and their use as analgesics
US4954506A (en) N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
MX2008006784A (en) Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006784

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200780003129.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007704286

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1641/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007211475

Country of ref document: AU

Ref document number: 2641817

Country of ref document: CA

Ref document number: 2008552803

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2007211475

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008135123

Country of ref document: RU

Kind code of ref document: A